var title_f9_63_10224="Endosc fundic gland polyp B";
var content_f9_63_10224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fundic gland polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a small polyp in the gastric fundus proven to be a fundic gland polyp after it was removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Y Graham, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10224=[""].join("\n");
var outline_f9_63_10224=null;
var title_f9_63_10225="Linear EUS celiac ganglia";
var content_f9_63_10225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear EUS celiac ganglia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear endosonography demonstrating three celiac ganglia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10225=[""].join("\n");
var outline_f9_63_10225=null;
var title_f9_63_10226="Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)";
var content_f9_63_10226=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Framingham08_F_form\" name=\"Framingham08_F_form\" onkeydown=\"clrResults();\" onkeyup=\"Framingham08_F_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          RiskFactors = (ln(Age) * 2.32888) + (ln(TotalChol) * 1.20904) - (ln(HDLChol) * 0.70833) +  (ln(SysBP) * SysBPFactor) + Cig + DM - 26.1931",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          Risk = 100 * (1 - 0.95012",
"          <sup>",
"           e",
"           <sup>",
"            (RiskFactors)",
"           </sup>",
"          </sup>",
"          )",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"Framingham08_F_fx(); minMaxCheck();\" onchange=\"Framingham08_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"Framingham08_F_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sys BP",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Sys_BP_param\" onblur=\"Framingham08_F_fx(); minMaxCheck();\" onchange=\"Framingham08_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Sys_BP_unit\" onchange=\"Framingham08_F_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Total Chol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Total_Chol_param\" onblur=\"Framingham08_F_fx(); minMaxCheck();\" onchange=\"Framingham08_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Total_Chol_unit\" onchange=\"Framingham08_F_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Chol\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_Chol\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              HDL Chol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"HDL_Chol_param\" onblur=\"Framingham08_F_fx(); minMaxCheck();\" onchange=\"Framingham08_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"HDL_Chol_unit\" onchange=\"Framingham08_F_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_HDL\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_HDL\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              On hypertension medication",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Sys_BP_Factor_pulldown\" onchange=\"Framingham08_F_fx();\" style=\"width:170px;\">",
"              <option value=\"2.76157\">",
"               No (2.76157)",
"              </option>",
"              <option value=\"2.82263\">",
"               Yes (2.82263)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Cigarette smoker",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Cig_pulldown\" onchange=\"Framingham08_F_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No (0)",
"              </option>",
"              <option value=\"0.52873\">",
"               Yes (0.52873)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Diabetes present",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"DM_pulldown\" onchange=\"Framingham08_F_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No (0)",
"              </option>",
"              <option value=\"0.69154\">",
"               Yes (0.69154)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Risk Factors",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Risk_Factors_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Risk",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Risk_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Risk_unit\" onchange=\"Framingham08_F_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Framingham08_F_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       This risk assessment tool is based on the Cox regression model of proportional hazards.",
"      </li>",
"      <li>",
"       Cardiovascular disease includes coronary disease, cerebrovascular disease, peripheral vascular arterial disease and heart failure.",
"      </li>",
"      <li>",
"       It may be applied to women who have had no prior history of cardiovascular disease.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        D'Agostino RB Sr, Vasan RS, Pencina MJ, et. al. General Cardiovascular Risk Profile for  Use in Primary Care. The Framingham Heart Study.",
"        <i>",
"         Circulation",
"        </i>",
"        . 2008 Jan 22.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10226=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Framingham08_F_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Framingham08_F_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sys_BP_param.value.indexOf(',') >= 0){ Sys_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Sys_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Sys_BP_unit.options[Sys_BP_unit.selectedIndex].value.split('|');",
"Sys_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Total_Chol_param.value.indexOf(',') >= 0){ Total_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Total_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Chol_unit.options[Total_Chol_unit.selectedIndex].value.split('|');",
"Total_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (HDL_Chol_param.value.indexOf(',') >= 0){ HDL_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(HDL_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = HDL_Chol_unit.options[HDL_Chol_unit.selectedIndex].value.split('|');",
"HDL_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"Sys_BP_Factor = parseFloat(Sys_BP_Factor_pulldown.options[Sys_BP_Factor_pulldown.selectedIndex].value);",
"Cig = parseFloat(Cig_pulldown.options[Cig_pulldown.selectedIndex].value);",
"DM = parseFloat(DM_pulldown.options[DM_pulldown.selectedIndex].value);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Risk_Factors =  (ln(Age) * 2.32888) + (ln(Total_Chol) * 1.20904) - (ln(HDL_Chol) * 0.70833) +  (ln(Sys_BP) * Sys_BP_Factor) + Cig + DM - 26.1931;",
"",
"if (doCalc) Risk_Factors_param.value = fixDP(Risk_Factors, dp);",
"",
"",
"",
"Risk =  100 * (1 - power(0.95012, eTo(Risk_Factors)));",
"",
"unit_parts = Risk_unit.options[Risk_unit.selectedIndex].value.split('|');",
"if (doCalc) Risk_param.value = fixDP((Risk - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_F_form){",
"",
"if (Age_param.value && Age < 19) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 19 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 80) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 80 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_F_form){",
"",
"Risk_Factors_param.value = '';",
"Risk_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f9_63_10226=null;
var title_f9_63_10227="Patient information: Cancer screening (The Basics)";
var content_f9_63_10227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/34/25123\">",
"         Patient information: Colon and rectal cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/26/27043\">",
"         Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/13/11475\">",
"         Patient information: Lung cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/14/27874\">",
"         Patient information: Ovarian cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/8/15491\">",
"         Patient information: Pap tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/27/32176\">",
"         Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/53/8019\">",
"         Patient information: Cervical cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7541\">",
"         Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/28/5570\">",
"         Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/15/6386\">",
"         Patient information: Ovarian cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/55/38770\">",
"         Patient information: Prostate cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cancer screening (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cancer-screening-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H453435767\">",
"      <span class=\"h1\">",
"       What is cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer screening is a way in which doctors check for some forms of cancer in the body. Cancer screening is done when a person feels healthy. The goal of cancer screening is to find those cancers that can be found as early as possible, before a person has any symptoms.",
"     </p>",
"     <p>",
"      Different tests can be used to screen for different types of cancers. The age at which screening starts varies depending on the type of cancer being screened for. That&rsquo;s because different cancers tend to strike at different times in a person&rsquo;s life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H453435774\">",
"      <span class=\"h1\">",
"       Why should I have cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer that is found early often is small and can sometimes be cured or treated easily. Treating certain cancers early can help people live longer. Sometimes, screening finds cells that do not yet show cancer, but that might turn into cancer cells. Doctors often treat this &ldquo;pre-cancer&rdquo; before it has a chance to become cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H453435781\">",
"      <span class=\"h1\">",
"       Does everyone have the same cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Not everyone is screened for the same types of cancer. And not everyone begins cancer screening at the same age. For example, people with a family history of certain cancers might begin screening at a younger age than people without a family history. People might have repeat screening tests at different times, too. Ask your doctor or nurse:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Which cancers should I be screened for?",
"       </li>",
"       <li>",
"        Do I have a choice about screening tests?",
"       </li>",
"       <li>",
"        At what age should I begin cancer screening?",
"       </li>",
"       <li>",
"        How often should I be screened?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H453435788\">",
"      <span class=\"h1\">",
"       Does an abnormal screening test result mean that I have cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not always. An abnormal screening test result means that you might have cancer. It does not mean that you definitely have cancer. If you have an abnormal result, your doctor or nurse will probably need to do other tests to find out for sure if anything is wrong. Try not to worry about having cancer until you follow up with your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H453435795\">",
"      <span class=\"h1\">",
"       Which cancers can people be screened for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some of the types of cancer for which screening tests are available are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Breast cancer",
"        </strong>",
"        &ndash; The main test used to screen for breast cancer is called a &ldquo;mammogram.&rdquo; Doctors do not always agree about when women should start having mammograms. But most women start around age 40 or 50. Women who have a strong family history of breast cancer might begin screening earlier. Work with your doctor or nurse to decide when to start breast cancer screening and at what age you might stop screening.",
"       </li>",
"       <li>",
"        <strong>",
"         Colon cancer &ndash;",
"        </strong>",
"        There are 5 or 6 screening tests for colon cancer. The choice of which test to have is up to you and your doctor. Doctors recommend that most people begin having colon cancer screening at age 50. Some people have an increased chance of getting colon cancer, because of a strong family history or certain medical conditions. These people might begin screening at a younger age.",
"       </li>",
"       <li>",
"        <strong>",
"         Cervical cancer",
"        </strong>",
"        &ndash; The main test used to screen for cervical cancer is called a &ldquo;Pap smear.&rdquo; Cervical cancer screening often begins when a woman turns 21. Doctors might add on another screening test after a woman turns 30. Women who are older than 65 might not need to continue cervical cancer screening. If you are older than 65, talk with your doctor about whether or not you should keep getting screened.",
"       </li>",
"       <li>",
"        <strong>",
"         Prostate cancer",
"        </strong>",
"        &ndash; The main test used to screen for prostate cancer is called a &ldquo;PSA test.&rdquo; It is unclear whether getting screened for prostate cancer can extend a man&rsquo;s life or help him feel better. For this reason, most experts do not recommend routine prostate cancer screening. Instead, experts recommend that each man work with his doctor to decide whether screening is right for him. In most cases, men should start discussing prostate cancer screening around the age of 50. Most doctors do not recommend screening for men age 75 or older or for men with serious health problems.",
"       </li>",
"       <li>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        &ndash; The main test used to screen for lung cancer is a special kind of x-ray called a &ldquo;low dose CT scan.&rdquo; If you are at high risk of lung cancer, for example because you smoke, ask your doctor about the risks and benefits of screening. But if you really want to reduce your chances of getting or dying from lung cancer, the best thing you can do is to stop smoking.",
"       </li>",
"       <li>",
"        <strong>",
"         Ovarian cancer",
"        </strong>",
"        &ndash; To screen for ovarian cancer, doctors can do a blood test, an imaging test called an ultrasound, or both. But these tests are not very accurate. Still, the tests are sometimes used in women with a family history of ovarian or breast cancer. For them, screening might begin at age 30 to 35. Screening is not recommended for women who do not have a family history of ovarian or breast cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H453435802\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"       Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/27/32176?source=see_link\">",
"       Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"       Patient information: Pap tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"       Patient information: Lung cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=see_link\">",
"       Patient information: Ovarian cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=see_link\">",
"       Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       Patient information: Cervical cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"       Patient information: Prostate cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       Patient information: Ovarian cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/63/10227?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15418 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10227=[""].join("\n");
var outline_f9_63_10227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435767\">",
"      What is cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435774\">",
"      Why should I have cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435781\">",
"      Does everyone have the same cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435788\">",
"      Does an abnormal screening test result mean that I have cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435795\">",
"      Which cancers can people be screened for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453435802\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=related_link\">",
"      Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=related_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=related_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=related_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/27/32176?source=related_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_63_10228="Thrush infant";
var content_f9_63_10228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Three examples of thrush (oral candidiasis) in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the white plaques on the inner lip and tongue (panel A) and on the buccal mucosa (panels B and C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10228=[""].join("\n");
var outline_f9_63_10228=null;
var title_f9_63_10229="Pseudoephedrine: Patient drug information";
var content_f9_63_10229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     see \"Pseudoephedrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"     see \"Pseudoephedrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Children's Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Nexafed&reg; [OTC];",
"     </li>",
"     <li>",
"      Oranyl [OTC];",
"     </li>",
"     <li>",
"      Silfedrine Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Maximum Strength Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudo-Tab&reg; [OTC];",
"     </li>",
"     <li>",
"      SudoGest 12 Hour [OTC];",
"     </li>",
"     <li>",
"      SudoGest Children's [OTC] [DSC];",
"     </li>",
"     <li>",
"      SudoGest [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Decongestant;",
"     </li>",
"     <li>",
"      Benylin&reg; D for Infants;",
"     </li>",
"     <li>",
"      Contac&reg; Cold 12 Hour Relief Non Drowsy;",
"     </li>",
"     <li>",
"      Drixoral&reg; ND;",
"     </li>",
"     <li>",
"      Eltor&reg;;",
"     </li>",
"     <li>",
"      PMS-Pseudoephedrine;",
"     </li>",
"     <li>",
"      Pseudofrin;",
"     </li>",
"     <li>",
"      Robidrine&reg;;",
"     </li>",
"     <li>",
"      Sudafed&reg; Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pseudoephedrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11892 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10229=[""].join("\n");
var outline_f9_63_10229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017974\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017976\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017975\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017980\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017981\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017983\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017978\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017979\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017984\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017985\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=related_link\">",
"      Pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=related_link\">",
"      Pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_63_10230="Statins: Possible noncardiovascular benefits";
var content_f9_63_10230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Statins: Possible noncardiovascular benefits",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10230/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10230/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10230/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10230/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/63/10230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid lowering, at least with statins, is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to cholesterol lowering and the primary and secondary prevention of cardiovascular disease, statin therapy may be associated with other benefits. Most of these other benefits have been found as associations in observational studies, rather than in randomized trials. As such, there is potential confounding and bias in that patients receiving better medical care, and those more adherent to medical therapy, may be more likely to be taking statins and also be at lower risk for certain noncardiovascular diseases.",
"   </p>",
"   <p>",
"    Potential noncardiovascular benefits of statins are discussed here. Side effects and toxicities of statins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some observational studies have suggested that statins may decrease the risk of dementia and at least one small randomized trial has suggested that statins may slow the progression of dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of dementia\", section on 'Statins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of dementia\", section on 'Risk factor control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/5-9\">",
"     5-9",
"    </a>",
"    ], observational studies have raised the possibility that use of statins may decrease overall risk of cancer and of specific cancers.",
"   </p>",
"   <p>",
"    In contrast, meta-analyses of randomized trials have consistently shown no effect of statins on cancer incidence or cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of individual patient data from 27 randomized trials of statins involving 174,149 patients found no increased risk of cancer death after a median follow-up of 4.9 years (RR 0.98, 95% CI 0.92-1.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis of 26 randomized trials of statins involving 86,936 patients, where the trials were required to have a mean follow-up of at least one year, also found no effect of statins on cancer incidence (odds ratio [OR] 1.02, CI 0.97-1.07) or cancer death (OR 1.01, CI 0.93-1.09) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/11\">",
"       11",
"      </a>",
"      ]. This lack of effect on cancer was true across different cancers and for various statin subtypes (ie, hydrophilic, lipophilic, natural, synthetic).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is implausible that a large early reduction in risk for a common cancer, such as the 55 percent reduction seen in a large case-control study of lung cancer within six months of initiating statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/14\">",
"     14",
"    </a>",
"    ], would have been missed in these meta-analyses. It is likely that most of the positive results seen in observational studies of statins and cancer are due to bias or confounding.",
"   </p>",
"   <p>",
"    In summary, there is no convincing evidence that statins increase or decrease the risk of cancer.",
"   </p>",
"   <p>",
"    Additionally, although an observational study suggested better outcomes in patients with cancer who were taking statins prior to their cancer diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/15\">",
"     15",
"    </a>",
"    ], similar concerns about residual confounding make these results unconvincing until confirmed in higher-quality trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RENAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-hoc analyses of clinical trials have raised the possibility that statins may be of some benefit in preserving renal function, both in patients with moderate chronic renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/17\">",
"     17",
"    </a>",
"    ] and in patients with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperlipidemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SEPSIS AND INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models of sepsis suggested that statins may improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/19-23\">",
"     19-23",
"    </a>",
"    ], and initial observational studies in bacteremic patients suggested that prior statin therapy may decrease the rates of severe sepsis and mortality from sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. This issue has been addressed in a number of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/27-33\">",
"     27-33",
"    </a>",
"    ], and a meta-analysis of observational studies found an association between statins and prevention of infection, but there was significant heterogeneity among studies as well as some evidence of publication bias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/34\">",
"     34",
"    </a>",
"    ]. A 2012 meta-analysis of observational and experimental studies also suggested that being on statin therapy reduces mortality in patients with community-acquired pneumonia; however, the authors were concerned about residual confounding affecting the results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2011 meta-analysis of 11 randomized trials of statins (n = 30,947) found no effect of statin therapy on infections (relative risk [RR] 1.00, 95% CI 0.96-1.05) or infection related mortality (RR 0.97, CI 0.83-1.13) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/36\">",
"     36",
"    </a>",
"    ]. In a subsequent report from the large JUPITER trial (n = 17,802), treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    was associated with a reduction in the risk of incident pneumonia (hazard ratio [HR] 0.83, CI 0.69-1.00), however, treatment did not appear to reduce the risk of sepsis (HR 1.21, CI 0.82-1.78), all infections (HR 0.98, CI 0.94-1.03), or severe infections (HR 0.90, CI 0.79-1.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/37\">",
"     37",
"    </a>",
"    ]. As multiple infection outcomes were studied, the apparent benefit in pneumonia may have been due to chance.",
"   </p>",
"   <p>",
"    Given these results, it is unlikely that prior statin therapy has an important effect on the risk or outcomes of infections. The utility of initiating statins in ill patients to prevent or ameliorate sepsis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link&amp;anchor=H21#H21\">",
"     \"Investigational and ineffective therapies for sepsis\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that statin therapy may decrease the risk of venous thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H28#H28\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that statins may increase bone formation, volume, and density, and reduce the risk of osteoporotic fractures, particularly in older patients; however, there have been conflicting results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that statins may lower blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=see_link\">",
"     \"Antihypertensive drugs and lipids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that statins may improve outcomes in patients with heart failure; this effect may be independent of the effect of statins on myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=see_link\">",
"     \"Statin therapy in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pancreatic and biliary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins may decrease the risk of requiring cholecystectomy for gallstones (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology of and risk factors for gallstones\", section on 'Statins'",
"    </a>",
"    ). Perhaps because of an effect on biliary tract stones, statins appear to reduce the risk of pancreatitis. In a meta-analysis of 16 randomized trials comparing statin therapy with placebo or control therapy in patients with normal or mildly elevated triglyceride levels (N = 113,800), statins reduced the risk of pancreatitis (relative risk 0.77, 95% CI 0.62-0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/40\">",
"     40",
"    </a>",
"    ]. This effect is likely not clinically important since in these trials, which had a mean follow-up of 4.1 years, only 0.27 percent of patients developed pancreatitis; 1175 such patients would need to receive statin therapy for five years to prevent one case of pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87225680\">",
"    <span class=\"h2\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies and models have suggested that statins could improve erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In a six-month randomized trial in 173 men with erectile dysfunction, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    produced a statistically-nonsignificant improvement on an erectile dysfunction index (1.28 versus 0.07 points, p = 0.27); this increase was also clinically insignificant based on the researchers&rsquo; a priori assumption that a three-point difference in the score would be clinically meaningful [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/44\">",
"     44",
"    </a>",
"    ]. Two randomized trials in men with erectile dysfunction initially unresponsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    could improve erectile responsiveness to sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10230/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional research is needed to determine whether statin therapy can have a clinically-important effect on erectile dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid lowering, at least with statins, is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of noncardiovascular benefits to statin therapy have been suggested. Many of these reflect associations in observational studies and may be due to confounding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bias. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Statins do not appear to increase or decrease the risk of cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/1\">",
"      Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/2\">",
"      Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/3\">",
"      Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med 2008; 121:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/4\">",
"      Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/5\">",
"      Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/6\">",
"      Khurana, V, Singh, T, Chalasani, R, et al. Statins do not reduce colon cancer risk in humans: a case control study. Gastroenterology 2004; 126 (Suppl):A452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/7\">",
"      Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/8\">",
"      Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/9\">",
"      Eliassen AH, Colditz GA, Rosner B, et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005; 165:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/10\">",
"      Cholesterol Treatment Trialists&rsquo; (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/11\">",
"      Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/12\">",
"      Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/13\">",
"      Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7:e29849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/14\">",
"      Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/15\">",
"      Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/16\">",
"      Caporaso NE. Statins and cancer-related mortality--let's work together. N Engl J Med 2012; 367:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/17\">",
"      Tonelli M, Moy&eacute; L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/18\">",
"      Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/19\">",
"      Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/20\">",
"      Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/21\">",
"      Giusti-Paiva A, Martinez MR, Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/22\">",
"      Terblanche M, Almog Y, Rosenson RS, et al. Statins: panacea for sepsis? Lancet Infect Dis 2006; 6:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/23\">",
"      Terblanche M, Almog Y, Rosenson RS, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/24\">",
"      Stefanec T. The effects of statins on mortality rates among bacteremic patients. Clin Infect Dis 2002; 34:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/25\">",
"      Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/26\">",
"      Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/27\">",
"      Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/28\">",
"      Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 2007; 297:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/29\">",
"      Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/30\">",
"      Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008; 168:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/31\">",
"      Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/32\">",
"      Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011; 342:d1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/33\">",
"      Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/34\">",
"      Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/35\">",
"      Chopra V, Rogers MA, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012; 125:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/36\">",
"      van den Hoek HL, Bos WJ, de Boer A, van de Garde EM. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ 2011; 343:d7281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/37\">",
"      Novack V, MacFadyen J, Malhotra A, et al. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 2012; 184:E367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/38\">",
"      Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/39\">",
"      Sp&oacute;sito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/40\">",
"      Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/41\">",
"      Gokce M, G&uuml;lpnar &Ouml;, &Ouml;zt&uuml;rk E, et al. Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol 2012; 44:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/42\">",
"      La Vignera S, Condorelli RA, Vicari E, Calogero AE. Statins and erectile dysfunction: a critical summary of current evidence. J Androl 2012; 33:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/43\">",
"      Park K, Cho SY, Kim SW. Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes. Int J Androl 2011; 34:e468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/44\">",
"      Trivedi D, Kirby M, Wellsted DM, et al. Can simvastatin improve erectile function and health-related quality of life in men aged &ge;40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2013; 111:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/45\">",
"      El-Sisi AA, Hegazy SK, Salem KA, Abdelkawy KS. Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase. Int J Impot Res 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10230/abstract/46\">",
"      Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010; 22:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4552 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10230=[""].join("\n");
var outline_f9_63_10230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SEPSIS AND INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pancreatic and biliary effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87225680\">",
"      Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=related_link\">",
"      Investigational and ineffective therapies for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_63_10231="Corneal ulcers";
var content_f9_63_10231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75303%7EPC%2F55332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75303%7EPC%2F55332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal infiltrates or ulcers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two small corneal white spots that are either infiltrates or ulcers (indicated by the arrows) are shown with normal light illumination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal infiltrates or ulcers with fluorescein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two small corneal areas of fluorescein staining (indicated by the arrows) that are either infiltrates or ulcers are shown with ultraviolet illumination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10231=[""].join("\n");
var outline_f9_63_10231=null;
var title_f9_63_10232="Pharmacology and side effects of azathioprine when used in rheumatic diseases";
var content_f9_63_10232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10232/contributors\">",
"     H Michael Belmont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10232/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10232/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/63/10232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) is the 1-methyl-4-nitro-5-imidazolyl derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    , a purine mimic antimetabolite [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/1\">",
"     1",
"    </a>",
"    ]. Its synthesis evolved from the same antibiotic and purine antimetabolite research in the late 1940s that led to the discovery and subsequent development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its use in preventing transplant rejection, AZA became available for use in the treatment of rheumatoid arthritis (RA) in patients who had not responded to less aggressive therapy. Use in RA was the indication that constituted the bulk of its use in the rheumatic diseases before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    and biologic agents became available for the treatment of RA in the late 1990s and early 2000s. AZA has subsequently also been used for the treatment of psoriatic arthritis, psoriasis, reactive arthritis, Beh&ccedil;et&rsquo;s disease, polymyositis, and systemic lupus erythematosus, and it has been used to sustain remissions in systemic vasculitis.",
"   </p>",
"   <p>",
"    The pharmacology of AZA, the side effects associated with its use, and the efficacy of AZA in the management of RA will be reviewed here. The role of AZA in the management of the different rheumatic diseases and of transplant recipients is presented in detail separately on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA is well-absorbed from the gastrointestinal tract. It has a serum half-life of 0.2 to 0.5 hours, resulting in a biologic half-life of approximately 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2\">",
"     2",
"    </a>",
"    ]. AZA is a prodrug; the action of glutathione in red blood cells causes the formation of the principal metabolite, 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prodrug AZA is approximately 30 percent protein-bound. Forty-five percent of the drug is excreted in the urine; the remainder is metabolized to 6-MP which is then further metabolized along competing routes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It undergoes catabolic oxidation to 6-thiouric acid. This reaction is catalyzed by xanthine oxidase, which is concentrated in the intestine and liver.",
"     </li>",
"     <li>",
"      It is also metabolized along an anabolic pathway to several metabolites including 6-methylmercaptopurine (6-MMP), 6-methyl-thioinosine 5'-monophosphate, and 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"       thioguanine",
"      </a>",
"      (6-TG). Two enzymes are responsible for catalyzing these reactions: thiopurine methyltransferase (TPMT), and hypoxanthine phosphoribosyl transferase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative accumulation of these metabolites depends upon genetic polymorphisms of the individual enzymes. The toxicity of AZA and 6-MP is predominantly related the activity of TPMT. In particular, deficiency of this enzyme causes 6-MP to be preferentially metabolized toward 6-TG nucleotides, which appear to account for much of the toxicity related to 6-MP. Low TPMT activity has been observed in up to 11 percent of the population, with 0.3 percent having negligible activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacogenetics and TPMT testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is uncertainty regarding the benefits of routine testing for thiopurine s-methyltransferase (TPMT) deficiency (MIM #187680) before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ; both genotyping and functional assays for this enzyme are available commercially. The author does not routinely perform such testing but initiates therapy at a low dose with close monitoring as the dose is gradually increased. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Dosing and monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    TPMT is responsible for the metabolism of thiopurines, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    . Variation in the TPMT gene can result in functional inactivation of the enzyme and in a markedly increased risk of life-threatening myelosuppression. For this reason, TPMT testing is recommended by the US Food and Drug Administration (FDA) prior to treatment with a thiopurine. However, TPMT genotyping has not been universally adopted, and the cost effectiveness and optimal clinical circumstances in which to perform routine testing are not well-defined.",
"   </p>",
"   <p>",
"    Expert opinions differ regarding the role of TPMT genotyping prior to the administration of thiopurines for treatment of inflammatory and autoimmune disorders. Some advocate routine testing while others, citing the low frequency of homozygous variants among Caucasians and the fact that the majority of patients who develop myelosuppression while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    do not have detectable TPMT gene mutations, disagree with this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Examples of the clinical observations regarding such testing include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 67 patients given AZA, for example, five of six individuals heterozygous for a mutant allele (as assessed by polymerase chain reaction-based assays) discontinued therapy within one month of drug initiation because of low leukocyte counts [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/4\">",
"       4",
"      </a>",
"      ]. AZA was given for a significantly longer period to those with wild-type alleles compared with patients with gene mutations (39 versus 2 weeks, respectively). In contrast, there was no association between TPMT alleles and AZA toxicity in a study of 342 patients with systemic lupus erythematosus (SLE) in Korea [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar considerations to those with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      apply to the use of 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      . In a series of 180 children with acute lymphoblastic leukemia, the cumulative incidence of dose reductions in 6-mercaptopurine due to drug toxicity was 7 percent in the 161 children with two wild-type TPMT alleles, was 35 percent in the 17 children with one mutant allele, and was 100 percent in the two children with two mutant alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/6\">",
"       6",
"      </a>",
"      ]. Lowering the 6-mercaptopurine dose in the last two groups permitted administration of the full protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Target serum levels of the metabolite 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    (6-TG) can also be used to help predict efficacy and toxicity. In an open-label study of AZA therapy for 50 patients with active SLE, pretreatment TPMT status facilitated dosing of AZA necessary to achieve appropriate serum levels of 6-TG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genes are also likely to play a role in determining AZA toxicity. As an example, polymorphisms of glutathione-S-transferase have also been associated with AZA-related adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with AZA and with the xanthine oxidase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    are also at increased risk for side effects. The relationship with allopurinol is sufficiently predictable that the two drugs should",
"    <strong>",
"     not",
"    </strong>",
"    be used together, if possible. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bone marrow suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA is available as 50 mg tablets and as AZA sodium powder for injection which is then reconstituted to a concentration of 10",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"    The tablet should be protected from light and should be stored in well-closed containers at a temperature that does not exceed 40&ordm;C. The solution should be refrigerated and will be stable for approximately two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracellular metabolism of 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    by hypoxanthine guanine phosphoribosyltransferase (HGPRT) produces thioinosinic and thioguanylic acid (6-TG). These compounds suppress intracellular inosinic acid synthesis, thereby interfering with adenine and guanine ribonucleotide production [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. This reduction in intracellular purine synthesis results in decreased numbers of circulating B and T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], in reduced immunoglobulin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/11\">",
"     11",
"    </a>",
"    ], and in diminished interleukin (IL)-2 secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/12\">",
"     12",
"    </a>",
"    ]. AZA does not reduce serum levels of interleukin-6 or soluble interleukin-2 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another pathway that has been demonstrated to be inhibited by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    is the intracellular signaling interactions downstream of the necessary costimulatory binding by CD28 on the surface of CD4+ T cells to B7 molecules on antigen presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link&amp;anchor=H13#H13\">",
"     \"Transplantation immunobiology\", section on 'CD28, B7, and CTLA4'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A guanosine triphosphate (GTP)-binding protein (Rac1) loses its ability to effectively activate antiapoptotic signaling when 6-thio-GTP is bound instead of the natural GTP. As a consequence, binding of the T cell antigen receptor and CD4 molecule may lead to apoptosis rather than to activation and proliferation of the T cell. Confirmation of the study that provided the data for this mechanism is needed. However, if confirmed, novel approaches to immunosuppression using GTP analogs or inhibitors of other signaling proteins may be developed.",
"   </p>",
"   <p>",
"    Both of these mechanisms depend upon intracellular metabolites for the antineoplastic and immune modulating effects of AZA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/15\">",
"     15",
"    </a>",
"    ]. Serum drug levels are, therefore, of little value in monitoring treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the frequency of toxicity in patients with rheumatoid arthritis treated with AZA is comparable to that of other immune-modifying antirheumatic drugs, AZA must still be administered with great caution [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. The most common side effects of AZA at doses typically used in the treatment of rheumatic diseases include gastrointestinal intolerance, bone marrow suppression, and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia, nausea, and vomiting occur in up to 23 percent of patients treated with AZA; these symptoms usually begin soon after the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/17\">",
"     17",
"    </a>",
"    ]. In comparison, diarrhea occurs in less than 1 percent of patients, and a mild elevation of liver enzymes occurs in approximately 5 percent. Progression to cirrhosis has not been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dramatic gastrointestinal hypersensitivity reactions have been reported in a few patients, characterized by nausea, by vomiting, and often by diarrhea and fever. Other nonspecific symptoms which should alert the clinician to this hypersensitivity syndrome include rash, myalgias, malaise, elevation of liver enzymes, and occasional hypotension, all occurring within the first few weeks of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose-related marrow suppression results in leukopenia in up to 27 percent of patients and thrombocytopenia in up to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Mild leukopenia usually responds to a reduction in the daily dose of AZA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2\">",
"     2",
"    </a>",
"    ]. Thrombocytopenia occurs in up to 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, 0.3 percent of normal subjects have very low levels of thiopurine methyltransferase (TPMT); this abnormality is genetically determined [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The ensuing reduction in AZA metabolism results in a significant risk for myelosuppression and a macrocytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pharmacogenetics and TPMT testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of AZA accumulation and of possibly severe bone marrow toxicity is more predictable when AZA is given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/20\">",
"     20",
"    </a>",
"    ]. As a result, we generally",
"    <strong>",
"     avoid",
"    </strong>",
"    this combination. If the patient has severe gout and if allopurinol must be used, we have reduced the AZA dose (by at least 50 percent) and have carefully monitored the white blood cell count; however, discontinuation of AZA was eventually required in many such patients. A possible alternative is switching from AZA to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , which does not interact with allopurinol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Mycophenolate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections occur overall in up to 9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. Bacterial infections usually occur in the clinical setting of leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Viral infections, especially herpes zoster, occur in up to 6 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/10,22\">",
"     10,22",
"    </a>",
"    ]. Exacerbation of chronic viral hepatitis may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant recipients who have been treated with protocols including AZA have demonstrated a 50-fold to 100-fold increase in the relative risk of malignant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. The most common tumors are squamous cell carcinomas of the skin, non-Hodgkin lymphoma, Kaposi&rsquo;s sarcoma, in situ carcinomas of the uterine cervix, and carcinomas of the vulva and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/24\">",
"     24",
"    </a>",
"    ]. Skin cancer is most common, occurring in 20 to 37 percent of patients, depending in part upon sun exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The malignancy risk is considerably smaller in patients with rheumatoid arthritis treated with AZA, ranging from 1.4 to 8.7 percent relative risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/10,25,26\">",
"     10,25,26",
"    </a>",
"    ]. One early review suggested that comparative risk of neoplasms of the immune system may be higher with AZA versus other immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/27\">",
"     27",
"    </a>",
"    ]. In a more contemporary series, however, high disease activity in RA appears to confer greater risk of lymphoma than does treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA may cause temporary depression of spermatogenesis and a reduction in sperm viability. No specific recommendations have been made for men who are being treated with the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA is widely used in renal transplant recipients, and there is a relatively large experience during pregnancy. Although AZA is generally well-tolerated, among the complications that can occur are lower birth weights, prematurity, jaundice, respiratory distress syndrome, aspiration, and, in isolated cases, lymphopenia, as well as decreased immunoglobulin concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither teratogenicity nor serious harm to the fetus has been demonstrated when AZA is given alone or in combination with glucocorticoids in pregnant women with systemic lupus erythematosus and active glomerulonephritis. Most authorities, however, would recommend that AZA be avoided during pregnancy in women being treated for rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major drug interaction with AZA is, as noted above, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    which slows the elimination of 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    by inhibiting xanthine oxidase. Thus, the dose of AZA should be reduced significantly (50 to 75 percent) in patients treated with allopurinol, but this combination should be avoided if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     USE IN RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA has proven effective for treatment of several rheumatic diseases. Such use is described in detail separately. Briefly, the following examples illustrate some of these uses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In rheumatoid arthritis (RA), the findings suggest it is superior to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/29-33\">",
"       29-33",
"      </a>",
"      ], is comparably effective to parenteral gold [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/16\">",
"       16",
"      </a>",
"      ], and is probably less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/34\">",
"       34",
"      </a>",
"      ]. Its role in the treatment of RA is very limited. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link&amp;anchor=H266402509#H266402509\">",
"       \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'Resistant to standard therapies'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As an example, a 32-week crossover study of 17 patients using AZA in a dose of 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day demonstrated reductions in swollen joints by 50 percent, in the articular index by 33 percent, and in the erythrocyte sedimentation rate by 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/29\">",
"       29",
"      </a>",
"      ]. In a follow-up study, continued long-term improvement was documented despite a lower mean dose of AZA (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/30\">",
"       30",
"      </a>",
"      ]. On the other hand, withdrawal of AZA led to recrudescence of disease in 15 of 16 patients in another trial [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/32\">",
"       32",
"      </a>",
"      ]. At least one series has demonstrated a trend toward dose effect for both efficacy and toxicity of AZA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/33\">",
"       33",
"      </a>",
"      ]. This report of 28 patients treated for 24 weeks found that those taking 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day did significantly better than placebo, while those taking 1.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day had an intermediate effect. There is a limited published experience reporting on multitargeted therapy combining",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      with an injectable biologic [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AZA is also used in patients with polyarteritis nodosa and with several forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, usually for maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10232/abstract/37-40\">",
"       37-40",
"      </a>",
"      ]. The clinical use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in these disorders is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"       \"Treatment and prognosis of polyarteritis nodosa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Randomized trials using daily doses of AZA similar to those given in RA have also demonstrated benefit in small numbers of patients with psoriatic arthritis, reactive arthritis, Beh&ccedil;et&rsquo;s disease, inflammatory myopathies, and systemic lupus erythematosus. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DOSING AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use an initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and we obtain a complete blood count after two weeks of therapy to assure that the counts are stable. We then usually increase the daily dose by 50 mg (or approximately 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) each week to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    In patients with a higher target dose for a given medical condition or with an inadequate response after three months of therapy, we increase the dose as tolerated up to a maximum typically of 3",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    A lower dose is indicated in patients with renal insufficiency.",
"   </p>",
"   <p>",
"    We initially obtain a complete blood count (CBC), a platelet count, and liver function tests monthly, and we then perform testing every three months once a stable dose is achieved.",
"   </p>",
"   <p>",
"    Alternative approaches, including more gradual dose escalation and more frequent monitoring, are recommended by some experts.",
"   </p>",
"   <p>",
"    In patients who develop leukopenia (white blood cells",
"    <span class=\"nowrap\">",
"     &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    or thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    during therapy, the AZA dose should be reduced, or the drug should be discontinued. If a 50 percent reduction in the dose is associated with persistent cytopenia, then AZA should generally be permanently discontinued. Patients who develop macrocytosis should be closely monitored with more frequent CBCs (eg, every two weeks for month) once other major causes of macrocytosis have been excluded, including vitamin B12 and folate deficiency. Stable mild macrocytosis in the absence of vitamin deficiency is a potential side effect which is well-tolerated and which does not require discontinuation of medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1122252\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (AZA) is a derivative of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"       thioguanine",
"      </a>",
"      , a purine-mimic antimetabolite. It is well-absorbed from the gastrointestinal tract and has a biologic half-life of approximately 24 hours. AZA is a prodrug; the action of glutathione in red blood cells causes the formation of the principal metabolite, 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP). The prodrug AZA is approximately 30 percent protein-bound. Forty-five percent of the drug is excreted in the urine; the remainder is metabolized to 6-MP which is then further metabolized along competing routes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolism of 6-MP is by competing routes: catabolic oxidation to 6-thiouric acid, which is catalyzed by xanthine oxidase, and metabolism along an anabolic pathway to several metabolites, for which two enzymes are responsible, thiopurine methyltransferase (TPMT) and hypoxanthine phosphoribosyl transferase. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative accumulation of 6-MP metabolites depends upon genetic polymorphisms of the individual enzymes. The toxicity of AZA and 6-MP is predominantly related the activity of TPMT. Deficiency of this enzyme causes 6-MP to be preferentially metabolized toward 6-TG nucleotides, which appear to account for much of the toxicity related to 6-MP. Low TPMT activity has been observed in up to 11 percent of the population, with 0.3 percent having negligible activity. Analysis of the TPMT gene by use of commercially available genotyping or functional assays for the enzyme prior to the administration of AZA may help predict those individuals at risk for severe toxicity. However, other genes are also likely to play a role in determining AZA toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pharmacogenetics and TPMT testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracellular metabolites of 6-MP are responsible for a reduction in intracellular purine synthesis and for the antineoplastic and immune-modulating effects of AZA. Serum drug levels are, therefore, of little value in monitoring treatment. AZA causes decreased numbers of circulating B and T lymphocytes, reduced immunoglobulin synthesis, diminished interleukin-2 secretion, and inhibition of the intracellular signaling downstream of T-cell costimulation involving CD28-mediated pathways. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of toxicity of AZA in patients with rheumatoid arthritis (RA) is comparable to that of other immune-modifying antirheumatic drugs, and AZA must be administered with great caution. The most common side effects of AZA at doses typically used in the treatment of rheumatic diseases include gastrointestinal intolerance, bone marrow suppression, and infection. The increase in relative risk of malignancy in patients with RA is small, in contrast with the effects of AZA in renal transplant recipients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major drug interaction with AZA is with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      , which slows the elimination of 6-MP by inhibiting xanthine oxidase. Thus, the dose of AZA should be reduced significantly (50 to 75 percent) in patients treated with allopurinol, but this combination should be avoided if possible. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have demonstrated that AZA is more effective than placebo in the treatment of rheumatoid arthritis. Its efficacy appears to be comparable to other agents such as gold and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , although it is probably not as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . AZA is also used for remission maintenance in ANCA-associated vasculitis and in the treatment of systemic lupus erythematosus, inflammatory myopathy, Beh&ccedil;et&rsquo;s disease, and other disorders. Such uses are discussed separately. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Use in rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the treatment of rheumatic diseases, AZA is generally begun at a dose of 25 to 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the first week to test for drug hypersensitivity. The dose is then increased incrementally by 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day every four to six weeks until the desired response is seen or until a maximal total dose of 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day is reached. A lower dose is indicated in patients with renal insufficiency. A complete blood count and platelet count should be monitored every two weeks during dose escalation and every four to six weeks after a stable dose is achieved. Some experts suggest liver enzyme testing every six to eight weeks during AZA therapy. The AZA dose should be reduced or discontinued in patients who develop leukopenia or thrombocytopenia. Patients who develop macrocytosis should be more closely monitored once the usual causes, such as vitamin B12 deficiency, have been excluded. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Dosing and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7718912\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate would like to acknowledge William S Wilke, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/1\">",
"      Elion GB. The purine path to chemotherapy. Science 1989; 244:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/2\">",
"      Huskisson EC. Azathioprine. Clin Rheum Dis 1984; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/3\">",
"      Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/4\">",
"      Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/5\">",
"      Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/6\">",
"      Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/7\">",
"      Askanase AD, Wallace DJ, Weisman MH, et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 2009; 36:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/8\">",
"      Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/9\">",
"      Elion GB, Hitchings GH. Azathioprine. Handbook Exp Pharmacol 1975; 38:404.",
"     </a>",
"    </li>",
"    <li>",
"     McKendry RJR. Pruine analogues. In: Second Line Agents in the Treatment of Rheumatic Diseases, Dixon J, Furst BE (Eds), Marcel Decker, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/11\">",
"      Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 1982; 306:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/12\">",
"      Bacon PA, Salmon M. Modes of action of second-line agents. Scand J Rheumatol Suppl 1987; 64:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/13\">",
"      Crilly A, McInnes IB, Capell HA, Madhok R. The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. Scand J Rheumatol 1994; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/14\">",
"      Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/15\">",
"      Nyhan WL, Sweetman L, Carpenter DG, et al. Effects of azathiprine in a disorder of uric acid metabolism and cerebral function. J Pediatr 1968; 72:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/16\">",
"      Currey HL, Harris J, Mason RM, et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J 1974; 3:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/17\">",
"      Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/18\">",
"      Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 1982; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/19\">",
"      Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982; 222:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/20\">",
"      Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/21\">",
"      Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol 1976; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/22\">",
"      Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989; 32:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/23\">",
"      Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/24\">",
"      Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/25\">",
"      Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/26\">",
"      Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/27\">",
"      Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/28\">",
"      Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/29\">",
"      Urowitz MB, Gordon DA, Smythe HA, et al. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum 1973; 16:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/30\">",
"      Hunter T, Urowitz MB, Gordon DA, et al. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum 1975; 18:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/31\">",
"      Cade R, Stein G, Pickering M, et al. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J 1976; 69:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/32\">",
"      Mason M, Currey HL, Barnes CG, et al. Azathioprine in rheumatoid arthritis. Br Med J 1969; 1:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/33\">",
"      Woodland J, Chaput de Saintonge DM, Evans SJ, et al. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann Rheum Dis 1981; 40:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/34\">",
"      Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991; 114:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/35\">",
"      Perdriger A, Mariette X, Kuntz JL, et al. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol 2006; 33:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/36\">",
"      Caramaschi P, Canestrini S, Biasi D, et al. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. Recenti Prog Med 2002; 93:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/37\">",
"      Brandwein S, Esdaile J, Danoff D, Tannenbaum H. Wegener's granulomatosis. Clinical features and outcome in 13 patients. Arch Intern Med 1983; 143:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/38\">",
"      Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/39\">",
"      Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10232/abstract/40\">",
"      Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7994 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10232=[""].join("\n");
var outline_f9_63_10232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1122252\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacogenetics and TPMT testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      USE IN RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DOSING AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1122252\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7718912\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_63_10233="CT scan and US acute calculous cholecystitis";
var content_f9_63_10233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Computed tomographic (CT) scan and ultrasound in a patient with acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan (A and B) shows a thick walled and distended gallbladder (thick white arrow) with pericholecystic induration (yellow arrowheads). However, it does not reveal gallstones. The radiologic differential diagnosis includes acute calculous and acalculous cholecystitis. The ultrasound (C and D) confirms the presence of a distended gallbladder (thick white arrow) with stones (black arrow), and the presence of tumefactive sludge (short yellow arrow). The thin white arrow shows a small amount of fluid in the gallbladder fossa. These findings are consistent with acute calculous cholecystitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10233=[""].join("\n");
var outline_f9_63_10233=null;
var title_f9_63_10234="Heat stroke in children";
var content_f9_63_10234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heat stroke in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10234/contributors\">",
"     Paul Ishimine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10234/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/63/10234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/63/10234/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/63/10234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia is defined as elevation of core body temperature above the normal diurnal range of 36 to 37.5&ordm;C (96.8 to 99.5&ordm;F) due to failure of thermoregulation. Hyperthermia is not synonymous with the more common sign of fever, which is induced by cytokine activation during inflammation and regulated at the level of the hypothalamus. Heat-related illnesses range from minor syndromes to life-threatening processes. While there are many manifestations of heat-related illnesses, all heat-related illnesses result from excessive heat stress caused by an increased environmental heat burden, an inability of the body to dissipate endogenous heat, or a combination of these two factors. Heat stroke is the most severe heat-related illness and can rapidly lead to death without prompt treatment.",
"   </p>",
"   <p>",
"    The manifestations, evaluation, and management of heat stroke in children will be reviewed here. Other forms of heat illness in children and hyperthermia in the adult patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link\">",
"     \"Heat illness (other than heat stroke) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEAT STROKE DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat stroke is defined as a core temperature &ge;40&ordm;C (104&ordm;F) accompanied by central nervous system dysfunction in patients with environmental heat exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/1\">",
"     1",
"    </a>",
"    ]. While anhidrosis (lack of sweating) is frequently present, especially with classic heat stroke, this is not an absolute diagnostic criterion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/1\">",
"     1",
"    </a>",
"    ]. This condition represents a failure of the body's ability to maintain thermoregulatory homeostasis. Heat stroke is further classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic (nonexertional) heat stroke",
"      </strong>",
"      &ndash; Classic heat stroke arises from environmental exposure to heat and is more common in younger children who are unable to escape from hot environments and those with underlying chronic medical conditions that impair thermoregulation (",
"      <a class=\"graphic graphic_table graphicRef73292 \" href=\"UTD.htm?2/14/2285\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Exertional heat stroke",
"      </strong>",
"      &ndash; Exertional heat stroke generally occurs in young, otherwise healthy individuals who engage in heavy exercise during periods of high ambient temperature and humidity. Typical patients are athletes and military recruits in basic training [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest rates of death from heat-related illness are in the elderly population and in adult patients with comorbid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/4-8\">",
"     4-8",
"    </a>",
"    ], but children are also at risk for heat-related illnesses. For example, young children, who cannot operate car door locks or who are restrained in car seats, may suffer morbidity or mortality when left unattended in vehicles, as temperatures inside a closed vehicle rapidly rise to dangerous levels even when ambient temperature is only moderately high [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Death from hyperthermia has occurred rarely in infants who were heavily bundled in their cribs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Education of parents regarding the high risk of leaving young children unattended in cars appears warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Key components of guidance include reinforcing the vulnerability of infants and young children to heat stress, the rapidity with which temperature may rise in a locked car, and the importance of keeping cars locked when not in use.",
"   </p>",
"   <p>",
"    Among teenage athletes, heat illness is the third major cause of death behind traumatic and cardiac causes of death [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. The highest rate of nonfatal heat illness in US high school athletes is found among American football players who account for 4.5 episodes of heat illness and limitation of athletic activity per 100,000 athlete-exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/20\">",
"     20",
"    </a>",
"    ]. American football also was the leading activity associated with an emergency department evaluation for heat illness in US patients &le;19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Approximately two-thirds of these episodes occur in August, and increased body-mass index (ie, being overweight or obese) appears to pose a significant risk. Prescription amphetamines for ADHD and dietary supplements, including creatine, may also contribute to subclinical dehydration and heat stroke in selected athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/23\">",
"     23",
"    </a>",
"    ]. Since creatine supplementation may increase serum creatinine concentrations, this supplement may act as a false indicator of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heat illness in athletes is potentially preventable. Key components of a successful strategy include age-appropriate periods of acclimatization; emphasis on proper hydration before, during, and after organized sports activities; and awareness of ambient temperatures with limitation of activities when heat poses a significant risk (",
"    <a class=\"graphic graphic_table graphicRef53860 \" href=\"UTD.htm?10/21/10588\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H13#H13\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Prevention of heat illness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Temperature homeostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body temperature is maintained within a narrow range by balancing heat load with heat dissipation. The body's heat load results from both metabolic processes and absorption of heat from the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/25\">",
"     25",
"    </a>",
"    ]. As core temperature rises, the preoptic nucleus of the anterior hypothalamus stimulates efferent fibers of the autonomic nervous system to produce sweating and cutaneous vasodilation to allow for reduction of body heat.",
"   </p>",
"   <p>",
"    Evaporation is the principal mechanism of heat loss in a hot environment, but this becomes ineffective above a relative humidity of 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/26\">",
"     26",
"    </a>",
"    ]. The other major methods of heat dissipation &ndash; radiation (emission of infrared electromagnetic energy), conduction (direct transfer of heat to an adjacent, cooler object), and convection (direct transfer of heat to convective air currents) &ndash; cannot efficiently transfer heat when environmental temperature exceeds skin temperature (typically 35&ordm;C or 95&ordm;F).",
"   </p>",
"   <p>",
"    Temperature elevation is accompanied by an increase in oxygen consumption and metabolic rate, resulting in hyperpnea and tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/2\">",
"     2",
"    </a>",
"    ]. Above 42&ordm;C (108&ordm;F), oxidative phosphorylation becomes uncoupled, and a variety of enzymes cease to function. Hepatocytes, vascular endothelium, and neural tissue are most sensitive to these effects, but all organs may be involved. As a result, these patients are at risk of multiorgan failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several key anatomic and physiologic differences exist between children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]; however, children do not appear to be at higher risk for heat illness when compared to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/28,30\">",
"     28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Heat production",
"      </strong>",
"      &ndash; Children produce more metabolic heat per kilogram of body weight because they have a higher basal metabolic rate than adults [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Body surface area",
"      </strong>",
"      &ndash; Younger children have a higher surface area to mass ratio, resulting in a greater rate of heat absorption in hot environments [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/29\">",
"       29",
"      </a>",
"      ]. However, body composition (especially an increase in body fat) and lack of fitness are likely more important contributors to susceptibility to heat illness in older children and adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Blood circulation",
"      </strong>",
"      &ndash; Children have a smaller absolute blood volume which limits the potential of blood borne heat transfer from the body core to the body surface where this heat can be dissipated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/31\">",
"       31",
"      </a>",
"      ]. In addition, children have a lower cardiac output at a given metabolic rate than adults, further limiting heat dissipation during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sweat production",
"      </strong>",
"      &ndash; Children have a lower rate of sweating than adults as a result of a lower sweat rate per gland and begin sweating at a higher body temperature [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27,32,33\">",
"       27,32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fluid replenishment",
"      </strong>",
"      &ndash; Children are more likely to inadequately replenish fluid losses during prolonged exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/28,29,34,35\">",
"       28,29,34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Acclimatization",
"      </strong>",
"      &ndash; Physiologic changes that result in increased heat tolerance include increased rate of sweating, a lower temperature threshold for sweating, reduced electrolyte losses in sweat, lower heart rate, increased aldosterone production with decreased urinary sodium, and lower core and skin temperatures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Children achieve these adaptations to a hot environment more slowly than adults and typically require 10 to 14 days to achieve adequate acclimatization [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27,29\">",
"       27,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of the risk for heat illness in children is attributable to general anatomic and physiologic characteristics, as well as environmental variables such as the ambient temperature and humidity levels. However, medical conditions may augment the susceptibility to heat illness in specific individuals (",
"    <a class=\"graphic graphic_table graphicRef73292 \" href=\"UTD.htm?2/14/2285\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heat stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children sustain serious heat-related injury when the critical thermal maximum (CTM) is exceeded. The CTM is defined as the degree of elevated body temperature and duration of heat exposure that can be tolerated before cell damage occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/38\">",
"     38",
"    </a>",
"    ]. Human thermal maximum is estimated as a core body temperature of 42&ordm;C (107.6&ordm;F) lasting between 45 minutes and eight hours.",
"   </p>",
"   <p>",
"    Physiologic heat stress causes cell injury through several proposed mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Production of acute-phase reactants (eg, cytokines) that initiate an inflammatory cascade [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/1,39\">",
"       1,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Direct injury to cells with denaturation of proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Direct injury to the vascular endothelium resulting in impaired microcirculation and disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intestinal ischemia and increased permeability followed by endotoxemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These pathophysiologic changes result in a systemic inflammatory response that results in multiple organ dysfunction and injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/1\">",
"     1",
"    </a>",
"    ]. The cascade of acute-phase reactants is countered, to some degree, by the production of heat shock proteins, which confer protection by preventing unfolding of denatured proteins and by impeding cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other medical conditions may coexist with or mimic heat stroke in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sepsis",
"      </strong>",
"      &ndash; Sepsis, especially in association with meningitis, can cause high fever and abnormal mental status. However, in most instances, the height of the fever does not exceed 41&ordm;C (105.8&ordm;F). Furthermore, a focus for infection (eg, pneumonia, cellulitis, meningitis) or an infectious prodrome (eg, upper respiratory infection, gastrointestinal complaints) is frequently present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link\">",
"       \"Approach to the septic-appearing infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central nervous system conditions",
"      </strong>",
"      &ndash; Central nervous system (CNS) pathology can result in an elevated body temperature and alteration in mental status. This can occur from acute or chronic injury isolated to the hypothalamus (eg, CNS infection, cerebrovascular accident, hemorrhage). However, traumatic brain injury involving any part of the brain can cause neurogenic fever [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/43\">",
"       43",
"      </a>",
"      ]. In addition, congenital anomalies of the brain may cause temperature dysregulation, including hyperthermia. In all of these conditions, the CNS abnormality precedes temperature elevation.",
"     </li>",
"     <li>",
"      <strong>",
"       Status epilepticus",
"      </strong>",
"      &ndash; Status epilepticus from any cause can result in hyperthermia. The most common cause of status epilepticus in young children is prolonged febrile seizures or underlying epilepsy. Rhabdomyolysis is a common comorbidity. Clinical features may be indistinguishable from heat stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18888?source=see_link\">",
"       \"Clinical features and complications of status epilepticus in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=see_link&amp;anchor=H19#H19\">",
"       \"Febrile seizures\", section on 'Febrile status epilepticus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Toxic overdose",
"      </strong>",
"      &ndash; Drug-related causes of seizures and hyperthermia (eg, overdose of cocaine, methamphetamine, amphetamine, MDMA [ecstasy], salicylates, anticholinergic agents) are important considerations in the hyperthermic child. Therapeutic levels of prescribed amphetamines or anticholinergic agents may also impair thermoregulation. In addition, salicylate intoxication also causes uncoupling of oxidative phosphorylation with hyperthermia and multiple organ failure. A history of drug exposure, an elevated salicylate level, or a positive toxicology screen for drugs of abuse is typically present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"       \"Cocaine: Acute intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"       \"MDMA (ecstasy) intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"       \"Methamphetamine intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"       \"Salicylate poisoning in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Serotonin syndrome",
"      </strong>",
"      &ndash; Hyperthermia commonly occurs in patients with serotonin syndrome, a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system (CNS). Although classically described as the triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities, serotonin syndrome is actually a spectrum of clinical findings ranging from benign to lethal. The recognition that the patient has been exposed to a serotonergic drug is essential to the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hemorrhagic shock and encephalopathy syndrome",
"      </strong>",
"      &ndash; Hemorrhagic shock and encephalopathy syndrome is a rare condition associated with hyperpyrexia, altered mental status, shock, disseminated intravascular coagulopathy, diarrhea, renal insufficiency, and liver failure, primarily in previously healthy infants under one year of age [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Although the etiology is unknown, this syndrome is very similar to heat stroke and is treated with supportive care and rapid cooling.",
"     </li>",
"     <li>",
"      <strong>",
"       Neuroleptic malignant syndrome",
"      </strong>",
"      &ndash; Neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to antipsychotic agents. In addition to hyperthermia, NMS is also characterized by \"lead pipe\" muscle rigidity, altered mental status, choreoathetosis, tremors, and evidence of autonomic dysfunction, such as diaphoresis, labile blood pressure, and arrhythmias. The history of antipsychotic drug exposure is a key component of the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid storm",
"      </strong>",
"      &ndash; Although most commonly seen in adults, children can, very rarely, manifest symptoms of thyroid storm including tachycardia, heart failure, and hyperpyrexia (temperature elevation up to 41.1&ordm;C [106&ordm;F]). Agitation, delirium, psychosis, stupor, or coma is usually associated with the diagnosis. Although thyroid storm can develop in patients with long-standing untreated hyperthyroidism, it is more often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, or an acute iodine load. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link\">",
"       \"Thyroid storm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignant hyperthermia",
"      </strong>",
"      &ndash; Malignant hyperthermia is a rare genetic disorder that manifests following exposure to certain agents, most commonly",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      and halothane. Other potent inhalational anesthetics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"       sevoflurane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"       desflurane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"       isoflurane",
"      </a>",
"      ) can also cause malignant hyperthermia. The onset of malignant hyperthermia is usually within one hour of the administration of general anesthesia, but rarely, may be delayed up to 10 hours after induction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for patients with heatstroke are elevated core temperature (&ge;40&ordm;C [104&ordm;F]) and central nervous system (CNS) abnormalities following environmental heat exposure. There is some overlap of symptoms between heat exhaustion and heat stroke (",
"    <a class=\"graphic graphic_table graphicRef65625 \" href=\"UTD.htm?11/55/12156\">",
"     table 3",
"    </a>",
"    ). While the distinction between heat exhaustion and heat stroke is sometimes unclear, children with elevated body temperature and CNS abnormalities should be treated as victims of heat stroke, given the significant morbidity and mortality associated with this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H9#H9\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Heat exhaustion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CNS symptoms may be subtle or deceptive and can be manifested as impaired judgment or inappropriate behavior. However, children commonly present with more significant neurologic symptoms such as seizures, delirium, hallucinations, ataxia, dysarthria, or coma.",
"   </p>",
"   <p>",
"    Other typical clinical manifestations include tachycardia and tachypnea. The skin may be flushed and warm or diaphoretic. Vomiting and diarrhea are also common. In addition, those patients with coagulopathy may demonstrate purpura, hemoptysis, hematemesis, melena, or hematochezia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of heat stroke is based upon a careful history and physical examination. The full differential diagnosis of hyperthermia should be considered in each patient. The context in which symptoms develop usually suggests the etiology (eg, evidence of heat stress in patients with heat stroke, serotonin syndrome in patients receiving serotonergic agents, sepsis among children with an infectious prodrome). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Core temperature measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core body temperature should be determined in all patients and continuously monitored. Rectal temperature is most commonly obtained, although esophageal, central venous, pulmonary artery, or bladder probe temperature are potential alternatives. Oral, axillary, or tympanic membrane temperatures are unreliable in treating heat illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heat stroke have abnormal laboratory findings, reflecting the systemic inflammatory response and end-organ damage resulting from heat stress. Laboratory studies should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid blood glucose to identify hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Blood gas determination (venous or arterial) to evaluate for the presence and severity of metabolic acidosis (especially in patients with exertional heat stroke) and respiratory alkalosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Complete blood count, prothrombin time (PT), partial thromboplastin time (PTT), and INR (International Normalized Ratio) to detect anemia and disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/41,42,47\">",
"       41,42,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum electrolytes to check for increased or decreased sodium and potassium levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) to assess for liver injury",
"     </li>",
"     <li>",
"      Blood urea nitrogen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum creatinine to identify prerenal azotemia or renal failure resulting from myoglobinuria",
"     </li>",
"     <li>",
"      Serum creatine kinase (CK), ionized or total calcium, and phosphate to detect rhabdomyolysis and associated hypocalcemia and hyperphosphatemia",
"     </li>",
"     <li>",
"      Urine rapid dipstick and microscopic urinalysis to diagnose myoglobinuria, which should be suspected in a patient who has a brown urine supernatant that tests positive for hemoglobin, but does not have increased red blood cells seen on microscopic analysis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toxicologic screening for drugs of abuse or prescribed medications in those patients for whom an illicit drug or medication side effect is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies may be indicated based on the patient's clinical presentation and response to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chest radiograph",
"      </strong>",
"      &ndash; A chest radiograph helps identify pulmonary edema in patients who develop persistent high output cardiac insufficiency and is useful in patients for whom pulmonary aspiration is a concern.",
"     </li>",
"     <li>",
"      <strong>",
"       Electrocardiogram",
"      </strong>",
"      &ndash; An electrocardiogram should be obtained in patients with electrolyte abnormalities (eg, hyperkalemia, hypokalemia, hypocalcemia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rhabdomyolysis.",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography",
"      </strong>",
"      &ndash; A computed tomography scan of the head should be obtained if a child has persistently altered mental status despite cooling or shows signs of increased intracranial pressure suggestive of cerebral edema or intracranial hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H9#H9\">",
"       \"Elevated intracranial pressure in children\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREHOSPITAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, children who have a loss of consciousness with exertion in warm weather should be treated as patients with heat stroke. However, the diagnosis of heat-related illness can be challenging in the prehospital environment. Core temperature measurement is generally not performed, and some cooling may have occurred prior to the arrival of prehospital personnel. Furthermore, the history in these patients is often unreliable, and mild environmental conditions may lead to a low level of suspicion for heat-related illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no studies that address the best method of prehospital cooling in the pediatric population. The following guidance for prehospital treatment is based on small trials and observational series performed in adult populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe heat-related illness require removal from the source of heat stress and rapid initiation of cooling, as the risk of morbidity and mortality for patients with heat-related illness is associated with the duration of hyperthermia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/3,50\">",
"       3,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We suggest that children with heat stroke undergo treatment with evaporative external cooling in the field. Evaporative cooling may be accomplished in the field by spraying patients with water or saline and fanning these patients, either manually or with ambulance fans or air-conditioners. Application of ice packs to the neck, axilla, and groin and administration of room temperature intravenous normal saline may complement evaporative cooling efforts. Interventions include the removal of clothing and external cooling techniques. The institution of prehospital cooling in children should not delay timely transportation to definitive care. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Rapid cooling'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prehospital and experimental studies in adults with exertional heat illness have come to different conclusions regarding the best method for cooling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water spray with fanning; application of ice packs to the neck, axillae, and groin; and infusion of cold normal saline (4&ordm;C [39&ordm;F]) all achieved reasonable cooling rates with a temperature reduction of 0.04 to 0.1&ordm;C per minute (0.07 to 0.18&ordm;F per minute) in a prospective evaluation of the three techniques in 11 healthy young men [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/51\">",
"       51",
"      </a>",
"      ]. In this study, where each subject was his own control, water spray with fanning provided superior cooling within the first 20 minutes of treatment.",
"     </li>",
"     <li>",
"      Because it provides the fastest cooling rate, prehospital cold water immersion of adults with exertional heat illness has also been advocated by some investigators based on observational studies and small trials [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/52-58\">",
"       52-58",
"      </a>",
"      ]. However, many of the patients in these studies met the definition of heat exhaustion (core temperature 38.5&ordm;C [101.3&ordm;F]) rather than heat stroke (core body temperature &ge;40&ordm;C [104&ordm;F]). The inability to have large quantities of cold water tubs available at athletic events also raises an important practical limitation. In addition, it remains unclear whether the inherent impediments of immersion to safe monitoring, resuscitation, and transport to definitive care outweigh the putative benefits. Thus, we do not favor the use of cold water immersion as a prehospital cooling measure in children with heat stroke. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Rapid cooling'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because significant cooling can occur during transport, the prehospital provider should relay the concern for heat-related illness to clinicians at the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HOSPITAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the careful assessment and support of airway, breathing, and circulation, the clinician should anticipate and aggressively manage hyperthermia, dehydration, rhabdomyolysis, disseminated intravascular coagulation, high output cardiac insufficiency, renal failure, and hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Rapid cooling'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of end-organ dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initial stabilization should focus on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Airway and breathing",
"      </strong>",
"      &ndash; Children with heat stroke frequently require basic or advanced airway management to maintain oxygenation and ventilation because of central nervous system effects (eg, coma, seizures). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Circulation",
"      </strong>",
"      &ndash; All patients with heat stroke need circulatory access, ideally with two large bore intravenous catheters or a central venous catheter. Initial therapy, however, can begin with a single peripheral catheter of any gauge or an intraosseous needle. Fluid resuscitation depends on the type of heat stroke and should replenish intravascular volume while avoiding fluid overload. Children with classic (nonexertional) heat stroke tend to only be mildly to moderately hypovolemic while those with exertional heat stroke may be moderately to severely hypovolemic. Thus, an initial rapid intravenous infusion of 20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of normal saline may be adequate fluid resuscitation for a patient with classic heat stroke while a child with exertional heat stroke may require 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of normal saline or more. Infusion of room temperature fluids assists with other methods of rapid cooling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who are unresponsive or minimally responsive to fluid resuscitation should undergo central venous pressure monitoring to guide additional therapy. Children with heat stroke may have decreased cardiac contractility and systemic vascular resistance as a byproduct of the heat stress and require initiation of vasopressor therapy to maintain adequate tissue perfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Disability",
"      </strong>",
"      &ndash; Altered mental status typically resolves once oxygenation, adequate tissue perfusion, and normothermia are achieved. Seizures should be treated with benzodiazepines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      intravenously).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rapid cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with heat stroke need to be treated aggressively, since the extent of end-organ damage is related to the duration of hyperthermia. No trials have compared cooling methods in children with either classic (nonexertional) or exertional heat stroke. The following recommendations are based on small trials and observational series performed in adult populations. Most studies have evaluated the impact of various types of cooling on the lowering of core body temperature in patients with exertional heat stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47,52-56\">",
"     47,52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       External cooling",
"      </strong>",
"      &ndash; We suggest that children with heat stroke undergo treatment with evaporative cooling. Application of ice packs to the neck, axilla, and groin and administration of room temperature intravenous normal saline may complement evaporative cooling efforts. Cooling measures should be stopped in pediatric heat stroke victims once the core temperature reaches 38&ordm;C (100.4&ordm;F) to prevent overshoot hypothermia.",
"      <br/>",
"      <br/>",
"      Although cold water immersion has been demonstrated to more rapidly cool core body temperature in young healthy adults with exercise-induced hyperthermia greater than 38.5&ordm;C (101.3&ordm;F), it is associated with significant discomfort, shivering, agitation, and combativeness in vulnerable populations, such as the elderly and, theoretically, may be more likely to cause overshoot hypothermia and bradycardia in children [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47,53,60\">",
"       47,53,60",
"      </a>",
"      ]. Cold water immersion also hampers efforts to maintain monitoring and ongoing resuscitation in these unstable patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47,60\">",
"       47,60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, no research has demonstrated superior outcomes for adult patients undergoing cold water immersion despite the more rapid drop in core body temperatures achieved with this method [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ]. Although a systematic review suggests that ice-water immersion of exercise-induced hyperthermia &gt;38.5&ordm;C (101.3&ordm;F) has the fastest cooling rate and is efficacious for exertional heat stroke (core temperature &ge;40&ordm;C [104&ordm;F]) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/53\">",
"       53",
"      </a>",
"      ], our view is that safety and efficacy for cold water immersion in exertional heat stroke is not established given that much of the data appears to be drawn from patients with heat exhaustion, not heat stroke.",
"      <br/>",
"      <br/>",
"      Isopropyl alcohol baths may lead to dermal absorption with toxicity in children and should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cooling rates and practical considerations are summarized as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Evaporative cooling",
"      </strong>",
"      &ndash; Evaporative cooling is achieved by spraying patients with tepid water (to minimize shivering) while fanning with high-flow fans to maximize air circulation. Cooling rates approaching 0.15&ordm;C per minute (0.27&ordm;F per minute) have been achieved in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ]. Both spray bottles and fans are usually available from hospital housekeeping services. Suspension of the patient on a mesh hammock during treatment enhances air circulation and may increase the rate of cooling. Alternatively, the patient may be placed on a cooling blanket to enhance conductive cooling. If tolerated, selective application of ice packs to the neck, axillae, and groin during evaporative cooling may be of additional benefit.",
"     </li>",
"     <li>",
"      <strong>",
"       Cold water immersion",
"      </strong>",
"      &ndash; Cold water immersion is another adjunctive cooling modality when evaporative cooling with or without selective ice application is not possible [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/53\">",
"       53",
"      </a>",
"      ]. It remains unclear whether the inherent impediments of immersion to safe monitoring and resuscitation in the hospital outweigh the putative benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other methods",
"      </strong>",
"      &ndash; In adults, cooling methods such as cooling blankets alone, covering patients in ice, covering patients with a wet sheet while fanning, or selective application of ice packs to the neck, axillae, and groin have very low to negligible cooling effect [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/53\">",
"       53",
"      </a>",
"      ]. However, cooling blankets with ice packs have been an effective form of total body cooling in infants after cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/63\">",
"       63",
"      </a>",
"      ] and might achieve rapid cooling in a small infant. If used, neuromuscular blockade or sedation may be necessary to prevent shivering. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pharmacologic therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Internal cooling",
"      </strong>",
"      &ndash; The most effective method of lowering the core body temperature quickly is the use of cardiopulmonary bypass; however, this highly specialized intervention is not rapidly available at most institutions. Newer, less invasive devices such as intravascular cooling catheters have been utilized to rapidly induce therapeutic hypothermia in order to treat or prevent neurologic injury in victims of cardiac arrest and may be useful in cooling efforts, although their effect has not been studied in heat stroke victims [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/58,64,65\">",
"       58,64,65",
"      </a>",
"      ]. Similarly, intravenous (IV) infusion of chilled normal saline via peripheral lines has been advocated although little data exist regarding its efficacy.",
"      <br/>",
"      <br/>",
"      Gastric, rectal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bladder lavage with cold isotonic fluids (eg, normal saline that has been iced) have been proposed as additional means of invasive cooling [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/60,66-68\">",
"       60,66-68",
"      </a>",
"      ]. However, it is not clear that these methods are any more effective than evaporative cooling or cold water immersion alone. For example, in canine studies, iced gastric lavage was inferior to evaporative cooling [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/67\">",
"       67",
"      </a>",
"      ], while iced peritoneal lavage was equivalent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/68\">",
"       68",
"      </a>",
"      ]. Thus, these methods are not routinely employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Duration of cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreases in core body temperature as measured by rectal temperature generally lag behind the actual drop in core temperature at the hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/69\">",
"     69",
"    </a>",
"    ]. For this reason, cooling measures are generally stopped in pediatric heat stroke victims once the core temperature reaches approximately 38&ordm;C (100.4&ordm;F) to prevent overshoot hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The amount of time required to reach this endpoint depends on the patient's initial temperature and the mode of cooling. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Rapid cooling'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications have a limited role in the management of heat stroke. However, pharmacologic measures taken to prevent shivering in heat stroke patients undergoing cooling may prevent increased endogenous heat production.",
"   </p>",
"   <p>",
"    The majority of studies investigating the use of medications to treat shivering have been conducted in perioperative settings, and no controlled studies have been conducted in patients with heat illness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/58\">",
"     58",
"    </a>",
"    ]. We suggest that patients with heat stroke receive benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously) to prevent shivering during cooling measures. Benzodiazepines have the added benefit of treating or preventing seizures. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Stabilization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although antipsychotic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ) have been used in adults to prevent shivering, their alpha-1 blocking properties may exacerbate hypotension in heat stroke victims. They also have a greater propensity to cause dystonia in children. Thus, they should be avoided.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43335?source=see_link\">",
"     Dantrolene",
"    </a>",
"    , a nonspecific skeletal muscle relaxant that acts by blocking the release of calcium from the sarcoplasmic reticulum, is used for the treatment of malignant hyperthermia and was once proposed as a treatment for hyperthermia from heat stroke. Although initial evidence suggested that dantrolene shortened cooling times in adults with heat stroke, additional small trials have not identified a consistent benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Thus, dantrolene is not routinely used. Some experts advocate the use of dantrolene in patients who are not responsive or are poorly responsive to initial cooling efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antipyretic medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) are ineffective for the treatment of hyperthermia in heat stroke victims and should not be used because they may exacerbate liver injury (acetaminophen) or compound coagulation disorders (nonsteroidal antiinflammatory agents, eg, ibuprofen).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of end-organ dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;After stabilization and rapid cooling, the child with heat stroke remains at high risk for multiple organ failure, metabolic abnormalities, and disorders of coagulation. The clinician should carefully evaluate for the following abnormalities and treat accordingly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhabdomyolysis with hyperkalemia, hypocalcemia, and hyperphosphatemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H29#H29\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute kidney injury (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"       \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyponatremic dehydration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Therapy according to serum sodium'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiogenic shock with low systemic vascular resistance (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiogenic and noncardiogenic pulmonary edema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link&amp;anchor=H4#H4\">",
"       \"Noncardiogenic pulmonary edema\", section on 'Permeability pulmonary edema due to ARDS'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liver failure - Treatment is supportive. Rarely, liver transplantation has been necessary in teenagers with heat stroke-associated liver failure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/73-76\">",
"       73-76",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"       \"Acute liver failure in adults: Management and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral edema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H20#H20\">",
"       \"Elevated intracranial pressure in children\", section on 'Management'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with heat stroke should be admitted to a pediatric critical care unit setting in order to maintain appropriate monitoring and to treat ongoing and delayed end-organ dysfunction. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of end-organ dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If there is no pediatric critical care coverage at the admitting hospital, the child should be resuscitated and promptly transferred to an appropriate institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in children with heat stroke is poorly characterized. Extrapolation from studies in adults suggests that morbidity or mortality are directly related to duration and degree of hyperthermia. Thus, heat stroke must be treated aggressively. In addition, prognosis depends on the patient population and type of heat stroke:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mortality",
"      </strong>",
"      &ndash; Mortality of up to 63 percent has been reported in elderly adults with classic heat stroke. In contrast, mortality is much lower (eg, 1 to 15 percent) in adolescents and young adults with exertional heat stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"       47",
"      </a>",
"      ]. Additional poor prognostic indicators for mortality include the height of the initial core body temperature and the number of organ systems affected during the course of treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic abnormalities",
"      </strong>",
"      &ndash; Permanent neurologic damage is more commonly seen in patients with core temperatures &gt;42&ordm;C (107.6&ordm;F) and consist of spasticity, ataxia, dysarthria, poor coordination, impaired memory, and behavioral changes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/59\">",
"       59",
"      </a>",
"      ]. Patients recovering from rapidly treated exertional or classic heat stroke with core body temperatures below this level may manifest some of these neurologic findings but typically recover fully [",
"      <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Heat intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat intolerance refers to a disorder in temperature homeostasis that is seen in heat stroke victims and that places them at greater risk for repeated heat illness. The clinician should anticipate some degree of heat intolerance in all children who recover from heat stroke. Children and their family should be counseled to avoid heat exposure until repeat evaluation establishes that they have fully recovered and a period of acclimatization has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Patients with severe heat stroke may have ongoing impaired physiologic response to exertion in hot environments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with exertional heat illness should only return to practice and competition when their temperature homeostasis is reestablished, generally after a minimum of one week of rest, full recovery from the initial insult based on repeat physical examination and laboratory testing (as needed to ensure all previously identified laboratory abnormalities have resolved), and a period of acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Once these conditions are met, the child should gradually return to physical activity over two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/77\">",
"     77",
"    </a>",
"    ]. The decision to return to play must be individualized, taking into consideration predisposing conditions for heat illness (eg, age, obesity) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/63/10234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition and treatment of milder forms of heat illness prevents progression to heat stroke. In addition, several precautions may be taken to help prevent heat stress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H13#H13\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Prevention of heat illness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=see_link\">",
"       \"Patient information: Heat stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heat stroke is defined as an elevated core temperature &ge;40&ordm;C (104&ordm;F) accompanied by central nervous system (CNS) dysfunction in children with environmental heat exposure. This condition represents a failure of the body's ability to maintain thermoregulatory homeostasis and is a true medical emergency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Heat stroke definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two forms of heat stroke exist:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Classic heat stroke arises from environmental exposure to heat and is more common in younger children who are unable to escape from hot environments and those with underlying chronic medical conditions that impair thermoregulation (",
"      <a class=\"graphic graphic_table graphicRef73292 \" href=\"UTD.htm?2/14/2285\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Exertional heat stroke occurs in young, otherwise healthy individuals who engage in heavy exercise during periods of high ambient temperature and humidity. Typical patients are young athletes and military recruits in basic training. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Heat stroke definition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of heat stroke is made on the basis of clinical findings. The full differential diagnosis of hyperthermia should be considered in each patient. In addition, there is some overlap of symptoms between heat exhaustion and heat stroke (",
"      <a class=\"graphic graphic_table graphicRef65625 \" href=\"UTD.htm?11/55/12156\">",
"       table 3",
"      </a>",
"      ). While the distinction between heat exhaustion and heat stroke is sometimes unclear, children with elevated body temperature and CNS abnormalities should be treated as victims of heat stroke. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rectal or other core body temperature measurement (eg, esophageal, bladder, or central venous temperature) is typically &ge;40&ordm;C (105&ordm;F) in children with heat stroke. However, the clinician should consider the possibility that prehospital cooling efforts have potentially lowered core body temperature prior to hospital assessment when making the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Core temperature measurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Prehospital considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CNS symptoms may be subtle and can manifest as impaired judgment or inappropriate behavior. However, children commonly present with more significant neurologic symptoms such as seizures, delirium, hallucinations, ataxia, dysarthria, or coma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other common clinical features include tachycardia, tachypnea, and hypotension. The skin may be flushed and warm (classic nonexertional heat stroke) or diaphoretic (exertional heat stroke). Vomiting and diarrhea are also common. In addition, those patients with coagulopathy may demonstrate purpura, hemoptysis, hematemesis, melena, or hematochezia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with heat stroke have abnormal laboratory findings, reflecting the systemic inflammatory response and end-organ damage resulting from heat stress. These patients warrant extensive studies to detect the presence of hypoglycemia, metabolic acidosis, anemia, disseminated intravascular coagulation, electrolyte disturbance, liver injury, prerenal azotemia, rhabdomyolysis, and exposure to illicit drugs or other toxins associated with hyperthermia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with heat stroke frequently require basic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced airway management to maintain oxygenation and ventilation because of central nervous system effects (eg, coma, seizures). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid resuscitation depends on the type of heat stroke and should seek to replenish intravascular volume while avoiding fluid overload. Patients unresponsive or minimally responsive to fluid resuscitation should undergo central venous pressure monitoring to guide additional therapy. Children with heat stroke often have decreased cardiac contractility and systemic vascular resistance as a byproduct of the heat stress and require initiation of vasopressor therapy to maintain adequate tissue perfusion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with heat stroke need to be treated aggressively, since the extent of end-organ damage is related to the duration of hyperthermia. We suggest that children with heat stroke undergo treatment with evaporative external cooling (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Application of ice packs to the neck, axilla, and groin and administration of room temperature intravenous normal saline may complement evaporative cooling efforts. Cooling measures should be stopped in pediatric heat stroke victims once the core temperature reaches 38&ordm;C (100.4&ordm;F) to prevent overshoot hypothermia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Rapid cooling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of cooling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Prehospital considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with heat stroke have evaporative external cooling started in the field (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the institution of prehospital cooling in children should not delay timely transportation to definitive care. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prehospital considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with heat stroke receive benzodiazepines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously) to prevent shivering during cooling measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In addition to rapid cooling and careful assessment and support of airway, breathing, and circulation, the clinician should anticipate and aggressively manage dehydration, rhabdomyolysis, disseminated intravascular coagulation, high output cardiac insufficiency, renal failure, and hepatic failure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of end-organ dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with heat stroke should be admitted to a pediatric critical care unit setting in order to maintain appropriate monitoring and to treat ongoing and delayed end-organ dysfunction. If there is no pediatric critical care coverage at the admitting hospital, the child should be resuscitated and promptly transferred to an appropriate institution. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/1\">",
"      Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/2\">",
"      Simon HB. Hyperthermia. N Engl J Med 1993; 329:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/3\">",
"      Heled Y, Rav-Acha M, Shani Y, et al. The \"golden hour\" for heatstroke treatment. Mil Med 2004; 169:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Heat-related mortality--Arizona, 1993-2002, and United States, 1979-2002. MMWR Morb Mortal Wkly Rep 2005; 54:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Heat-related deaths--Chicago, Illinois, 1996-2001, and United States, 1979-1999. MMWR Morb Mortal Wkly Rep 2003; 52:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Heat-related deaths--four states, July-August 2001, and United States, 1979-1999. MMWR Morb Mortal Wkly Rep 2002; 51:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Heat-related deaths--United States, 1999-2003. MMWR Morb Mortal Wkly Rep 2006; 55:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/8\">",
"      Dhainaut JF, Claessens YE, Ginsburg C, Riou B. Unprecedented heat-related deaths during the 2003 heat wave in Paris: consequences on emergency departments. Crit Care 2004; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/9\">",
"      McLaren C, Null J, Quinn J. Heat stress from enclosed vehicles: moderate ambient temperatures cause significant temperature rise in enclosed vehicles. Pediatrics 2005; 116:e109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/10\">",
"      Guard A, Gallagher SS. Heat related deaths to young children in parked cars: an analysis of 171 fatalities in the United States, 1995-2002. Inj Prev 2005; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/11\">",
"      King K, Negus K, Vance JC. Heat stress in motor vehicles: a problem in infancy. Pediatrics 1981; 68:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/12\">",
"      Roberts KB, Roberts EC. The automobile and heat stress. Pediatrics 1976; 58:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/13\">",
"      Krous HF, Nadeau JM, Fukumoto RI, et al. Environmental hyperthermic infant and early childhood death: circumstances, pathologic changes, and manner of death. Am J Forensic Med Pathol 2001; 22:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/14\">",
"      Bass M, Kravath RE, Glass L. Death-scene investigation in sudden infant death. N Engl J Med 1986; 315:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/15\">",
"      Bacon C, Scott D, Jones P. Heatstroke in well-wrapped infants. Lancet 1979; 1:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/16\">",
"      Coris EE, Ramirez AM, Van Durme DJ. Heat illness in athletes: the dangerous combination of heat, humidity and exercise. Sports Med 2004; 34:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/17\">",
"      Rice SG, American Academy of Pediatrics Council on Sports Medicine and Fitness. Medical conditions affecting sports participation. Pediatrics 2008; 121:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/18\">",
"      Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/19\">",
"      Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Heat illness among high school athletes --- United States, 2005-2009. MMWR Morb Mortal Wkly Rep 2010; 59:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal sports and recreation heat illness treated in hospital emergency departments--United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2011; 60:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/22\">",
"      Nelson NG, Collins CL, Comstock RD, McKenzie LB. Exertional heat-related injuries treated in emergency departments in the U.S., 1997-2006. Am J Prev Med 2011; 40:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/23\">",
"      Bailes JE, Cantu RC, Day AL. The neurosurgeon in sport: awareness of the risks of heatstroke and dietary supplements. Neurosurgery 2002; 51:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/24\">",
"      Yoshizumi WM, Tsourounis C. Effects of creatine supplementation on renal function. J Herb Pharmacother 2004; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/25\">",
"      Khosla R, Guntupalli KK. Heat-related illnesses. Crit Care Clin 1999; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/26\">",
"      Bross MH, Nash BT Jr, Carlton FB Jr. Heat emergencies. Am Fam Physician 1994; 50:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/27\">",
"      Bytomski JR, Squire DL. Heat illness in children. Curr Sports Med Rep 2003; 2:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/28\">",
"      Council on Sports Medicine and Fitness and Council on School Health, Bergeron MF, Devore C, et al. Policy statement&mdash;Climatic heat stress and exercising children and adolescents. Pediatrics 2011; 128:e741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/29\">",
"      Naughton GA, Carlson JS. Reducing the risk of heat-related decrements to physical activity in young people. J Sci Med Sport 2008; 11:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/30\">",
"      Rowland T. Thermoregulation during exercise in the heat in children: old concepts revisited. J Appl Physiol 2008; 105:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/31\">",
"      Falk B. Effects of thermal stress during rest and exercise in the paediatric population. Sports Med 1998; 25:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/32\">",
"      Falk B, Bar-Or O, Calvert R, MacDougall JD. Sweat gland response to exercise in the heat among pre-, mid-, and late-pubertal boys. Med Sci Sports Exerc 1992; 24:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/33\">",
"      Wagner JA, Robinson S, Tzankoff SP, Marino RP. Heat tolerance and acclimatization to work in the heat in relation to age. J Appl Physiol 1972; 33:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/34\">",
"      Bar-Or O, Dotan R, Inbar O, et al. Voluntary hypohydration in 10- to 12-year-old boys. J Appl Physiol 1980; 48:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/35\">",
"      Bar-Or O, Wilk B. Water and electrolyte replenishment in the exercising child. Int J Sport Nutr 1996; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/36\">",
"      Seto CK, Way D, O'Connor N. Environmental illness in athletes. Clin Sports Med 2005; 24:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/37\">",
"      Nielsen B, Hales JR, Strange S, et al. Human circulatory and thermoregulatory adaptations with heat acclimation and exercise in a hot, dry environment. J Physiol 1993; 460:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/38\">",
"      Bynum GD, Pandolf KB, Schuette WH, et al. Induced hyperthermia in sedated humans and the concept of critical thermal maximum. Am J Physiol 1978; 235:R228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/39\">",
"      Leon LR. Heat stroke and cytokines. Prog Brain Res 2007; 162:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/40\">",
"      Lim CL, Mackinnon LT. The roles of exercise-induced immune system disturbances in the pathology of heat stroke : the dual pathway model of heat stroke. Sports Med 2006; 36:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/41\">",
"      Mustafa KY, Omer O, Khogali M, et al. Blood coagulation and fibrinolysis in heat stroke. Br J Haematol 1985; 61:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/42\">",
"      Bouchama A, Bridey F, Hammami MM, et al. Activation of coagulation and fibrinolysis in heatstroke. Thromb Haemost 1996; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/43\">",
"      Thompson HJ, Pinto-Martin J, Bullock MR. Neurogenic fever after traumatic brain injury: an epidemiological study. J Neurol Neurosurg Psychiatry 2003; 74:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/44\">",
"      Gefen R, Eshel G, Abu-Kishk I, et al. Hemorrhagic shock and encephalopathy syndrome: clinical course and neurological outcome. J Child Neurol 2008; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/45\">",
"      Levin M, Pincott JR, Hjelm M, et al. Hemorrhagic shock and encephalopathy: clinical, pathologic, and biochemical features. J Pediatr 1989; 114:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/46\">",
"      Rinka H, Yoshida T, Kubota T, et al. Hemorrhagic shock and encephalopathy syndrome--the markers for an early HSES diagnosis. BMC Pediatr 2008; 8:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/47\">",
"      Bouchama A, Dehbi M, Chaves-Carballo E. Cooling and hemodynamic management in heatstroke: practical recommendations. Crit Care 2007; 11:R54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/48\">",
"      Bouchama A, De Vol EB. Acid-base alterations in heatstroke. Intensive Care Med 2001; 27:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/49\">",
"      Shapiro Y, Seidman DS. Field and clinical observations of exertional heat stroke patients. Med Sci Sports Exerc 1990; 22:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/50\">",
"      Vicario SJ, Okabajue R, Haltom T. Rapid cooling in classic heatstroke: effect on mortality rates. Am J Emerg Med 1986; 4:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/51\">",
"      Sinclair WH, Rudzki SJ, Leicht AS, et al. Efficacy of field treatments to reduce body core temperature in hyperthermic subjects. Med Sci Sports Exerc 2009; 41:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/52\">",
"      Smith JE. Cooling methods used in the treatment of exertional heat illness. Br J Sports Med 2005; 39:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/53\">",
"      McDermott BP, Casa DJ, Ganio MS, et al. Acute whole-body cooling for exercise-induced hyperthermia: a systematic review. J Athl Train 2009; 44:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/54\">",
"      Gaffin SL, Gardner JW, Flinn SD. Cooling methods for heatstroke victims. Ann Intern Med 2000; 132:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/55\">",
"      Clements JM, Casa DJ, Knight J, et al. Ice-Water Immersion and Cold-Water Immersion Provide Similar Cooling Rates in Runners With Exercise-Induced Hyperthermia. J Athl Train 2002; 37:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/56\">",
"      Proulx CI, Ducharme MB, Kenny GP. Effect of water temperature on cooling efficiency during hyperthermia in humans. J Appl Physiol 2003; 94:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/57\">",
"      Eshel GM, Safar P, Stezoski W. Evaporative cooling as an adjunct to ice bag use after resuscitation from heat-induced arrest in a primate model. Pediatr Res 1990; 27:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/58\">",
"      Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med 2009; 37:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/59\">",
"      Jardine DS. Heat illness and heat stroke. Pediatr Rev 2007; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/60\">",
"      Glazer JL. Management of heatstroke and heat exhaustion. Am Fam Physician 2005; 71:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/61\">",
"      McFadden SW, Haddow JE. Coma produced by topical application of isopropanol. Pediatrics 1969; 43:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/62\">",
"      Arditi M, Killner MS. Coma following use of rubbing alcohol for fever control. Am J Dis Child 1987; 141:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/63\">",
"      Hutchison JS, Doherty DR, Orlowski JP, Kissoon N. Hypothermia therapy for cardiac arrest in pediatric patients. Pediatr Clin North Am 2008; 55:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/64\">",
"      Broessner G, Beer R, Franz G, et al. Case report: severe heat stroke with multiple organ dysfunction - a novel intravascular treatment approach. Crit Care 2005; 9:R498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/65\">",
"      M&eacute;garbane B, R&eacute;si&egrave;re D, Delahaye A, Baud FJ. Endovascular hypothermia for heat stroke: a case report. Intensive Care Med 2004; 30:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/66\">",
"      Syverud SA, Barker WJ, Amsterdam JT, et al. Iced gastric lavage for treatment of heatstroke: efficacy in a canine model. Ann Emerg Med 1985; 14:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/67\">",
"      White JD, Riccobene E, Nucci R, et al. Evaporation versus iced gastric lavage treatment of heatstroke: comparative efficacy in a canine model. Crit Care Med 1987; 15:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/68\">",
"      White JD, Kamath R, Nucci R, et al. Evaporation versus iced peritoneal lavage treatment of heatstroke: comparative efficacy in a canine model. Am J Emerg Med 1993; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/69\">",
"      WYNDHAM CH, STRYDOM NB, COOKE HM, et al. Methods of cooling subjects with hyperpyrexia. J Appl Physiol 1959; 14:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/70\">",
"      Bouchama A, Cafege A, Devol EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med 1991; 19:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/71\">",
"      Channa AB, Seraj MA, Saddique AA, et al. Is dantrolene effective in heat stroke patients? Crit Care Med 1990; 18:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/72\">",
"      Hadad E, Cohen-Sivan Y, Heled Y, Epstein Y. Clinical review: Treatment of heat stroke: should dantrolene be considered? Crit Care 2005; 9:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/73\">",
"      Berger J, Hart J, Millis M, Baker AL. Fulminant hepatic failure from heat stroke requiring liver transplantation. J Clin Gastroenterol 2000; 30:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/74\">",
"      Hadad E, Ben-Ari Z, Heled Y, et al. Liver transplantation in exertional heat stroke: a medical dilemma. Intensive Care Med 2004; 30:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/75\">",
"      Pastor MA, P&eacute;rez-Aguilar F, Ortiz V, et al. [Acute hepatitis due to heatstroke]. Gastroenterol Hepatol 1999; 22:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/76\">",
"      Takahashi K, Chin K, Ogawa K, et al. Living donor liver transplantation with noninvasive ventilation for exertional heat stroke and severe rhabdomyolysis. Liver Transpl 2005; 11:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/77\">",
"      American College of Sports Medicine, Armstrong LE, Casa DJ, et al. American College of Sports Medicine position stand. Exertional heat illness during training and competition. Med Sci Sports Exerc 2007; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/78\">",
"      Royburt M, Epstein Y, Solomon Z, Shemer J. Long-term psychological and physiological effects of heat stroke. Physiol Behav 1993; 54:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/79\">",
"      Armstrong LE, De Luca JP, Hubbard RW. Time course of recovery and heat acclimation ability of prior exertional heatstroke patients. Med Sci Sports Exerc 1990; 22:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/80\">",
"      Epstein Y. Heat intolerance: predisposing factor or residual injury? Med Sci Sports Exerc 1990; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/63/10234/abstract/81\">",
"      Shapiro Y, Magazanik A, Udassin R, et al. Heat intolerance in former heatstroke patients. Ann Intern Med 1979; 90:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6596 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10234=[""].join("\n");
var outline_f9_63_10234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEAT STROKE DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Temperature homeostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heat stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Core temperature measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREHOSPITAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rapid cooling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Duration of cooling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of end-organ dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Heat intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/14/2285\" title=\"table 1\">",
"      Risk factors for heat illness in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/21/10588\" title=\"table 2\">",
"      Heat index and wet bulb globe temperature risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/55/12156\" title=\"table 3\">",
"      Heat stroke versus heat exhaustion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18888?source=related_link\">",
"      Clinical features and complications of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=related_link\">",
"      Heat illness (other than heat stroke) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=related_link\">",
"      Patient information: Heat stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_63_10235="Designation of genital HSV";
var content_f9_63_10235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical designation of genital herpes simplex virus infection (HSV)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary genital HSV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibodies to both HSV-1 and HSV-2 are absent at the time the patient acquires genital HSV due to HSV-1 or HSV-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonprimary first episode genital HSV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Acquisition&nbsp;of genital HSV-2 with preexisting antibodies to HSV-1",
"        </p>",
"        <p>",
"         or",
"        </p>",
"        <p>",
"         Acquisition of genital HSV-1 with preexisting antibodies to HSV-2*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recurrent genital HSV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactivation of genital HSV in which the HSV type recovered from the lesion is the same type as antibodies in the serum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;* This occurs extremely rarely.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10235=[""].join("\n");
var outline_f9_63_10235=null;
var title_f9_63_10236="Breast ca surveillance PI";
var content_f9_63_10236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Watching for cancer return after breast cancer treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of monitoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        What experts recommend",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Regular doctor visits",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         For the first three years after being treated for breast cancer, see your doctor or nurse every 3 to 6 months. During the 4th and 5th year after treatment, see your doctor or nurse every 6 to 12 months. After that, see your doctor or nurse once a year. Having these regular check-ups will give your doctor or nurse a chance to check for any signs of returning cancer.",
"        </p>",
"        <p>",
"         After treatment, it's good to have a doctor who is familiar with monitoring patients for cancer recurrence. If your primary care physician takes over monitoring, make sure he or she is in touch with your cancer specialists.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Symptom checks",
"        </strong>",
"       </td>",
"       <td>",
"        If you notice any symptoms that might signal the return of cancer, tell your doctor or nurse. Symptoms to look for include new lumps in the breast, bone pain, chest pain, belly pain, trouble breathing, or persistent headaches.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Genetic counseling or testing",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         If you are at higher-than-average risk of breast cancer recurrence consider genetic counseling or testing. High-risk groups include women with:",
"        </p>",
"        <ul>",
"         <li>",
"          Ashkenazi Jewish heritage",
"         </li>",
"         <li>",
"          A personal or family history of ovarian cancer",
"         </li>",
"         <li>",
"          A daughter, sister, or mother who was diagnosed with breast cancer before the age of 50",
"         </li>",
"         <li>",
"          Two or more relatives diagnosed with breast cancer at any age",
"         </li>",
"         <li>",
"          Breast cancer in both breasts or a relative who had breast cancer in both breasts",
"         </li>",
"         <li>",
"          A male relative with breast cancer",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mammograms",
"        </strong>",
"       </td>",
"       <td>",
"        After you have been treated, have a mammogram 1 year after the mammogram that led to the diagnosis but no earlier than 6 months after radiation therapy. You may also need other subsequent mammograms, depending on your individual situation. (Note that experts do not recommend breast MRI as a routine part of post-treatment monitoring.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10236=[""].join("\n");
var outline_f9_63_10236=null;
var title_f9_63_10237="Outcome typ atyp bronch car";
var content_f9_63_10237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Long-term survival after resection of typical and atypical bronchial carcinoids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Five&nbsp;year",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Ten&nbsp;year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Typical",
"       </td>",
"       <td class=\"subtitle3\">",
"        Atypical",
"       </td>",
"       <td class=\"subtitle3\">",
"        Typical",
"       </td>",
"       <td class=\"subtitle3\">",
"        Atypical",
"       </td>",
"       <td class=\"subtitle3\">",
"        Typical",
"       </td>",
"       <td class=\"subtitle3\">",
"        Atypical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Harpole H, 1992",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soga J, 1999",
"       </td>",
"       <td>",
"        1595",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beasley M, 2000",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gracia-Yuste M, 2000",
"       </td>",
"       <td>",
"        261",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferguson M, 2000",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fink G, 2001",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Filosso P, 2002",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fiala P, 2003",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaplan B, 2003",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        79*",
"       </td>",
"       <td>",
"        63*",
"       </td>",
"       <td>",
"        60*",
"       </td>",
"       <td>",
"        37*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardillo G, 2004",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rea F, 2007",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Machuca T, 2010",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Disease-specific survival.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10237=[""].join("\n");
var outline_f9_63_10237=null;
var title_f9_63_10238="Nicotine replacement therapy relevant to adolescents";
var content_f9_63_10238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nicotine replacement therapy relevant to adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Transdermal patches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patches are available without prescription for adults; a prescription is required in the United States for individuals under 18 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The advantages of patches are that they are very simple to use and provide steady action over the course of the day. However, patients may need an additional short-acting agent (gum, spray, or lozenge) to respond to acute nicotine craving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Several strengths are available; the patient should follow the package directions to choose the appropriate strength based on their history of tobacco use. Most heavy smokers begin with a high-strength patch (eg, 21 mg/patch), and gradually decrease the strength over 6 to 8 weeks. Patients who are light smokers or who weigh less than 100 lbs (45 kg) should start with a lower strength patch.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Each patch can be used for 24 hours. If patients have problems sleeping, they may prefer to remove the patch at bedtime (16 hour patch).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patches are applied to a clean, dry, hairless area of skin (usually trunk or neck) and removed at the end of the day (16 hours) or the next day (24 hours).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin irritation is the most common side effect; to minimize this problem rotate the patch to different sites each day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gum*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotine replacement therapy gum is available in 2 mg and 4 mg strengths without prescription for adults; a prescription is required in the United States for individuals under 18 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The advantage of nicotine gum is that it increases nicotine levels quickly, so it can be used to respond to an acute craving. For some patients gum is not effective because they do not use it often enough or chew long enough.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The nicotine from the gum is absorbed through the oral mucosa, and is optimized by a sequence of chewing and \"parking\" the gum between the cheek and gums. Chewing gum too vigorously usually results in more nicotine being swallowed. This is not dangerous but reduces nicotine absorption and may also cause local irritation and hiccups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most heavy smokers use the 4 mg strength gum. Patients who are light smokers or who weigh less than 100 lbs (45 kg) should start with the 2 mg strength.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with significant symptoms of nicotine dependence typically start with chewing a piece of gum every one to two hours, and use 10 to 24 pieces a day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Each piece of gum should be chewed slowly to release the nicotine. After a few minutes of chewing, the nicotine will be released, indicated by a hot peppery taste. The gum should then be \"parked\" between the cheek and gums so that the nicotine can be absorbed. The process of slowly chewing then \"parking\" the gum should be repeated every few minutes for 20 - 30 minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lozenge*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral lozenges are available without prescription for adults; a prescription is required in the United States for individuals under 18 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Like nicotine gum, lozenges increase nicotine levels rapidly (peak levels at 20-30 minutes) and may be helpful for acute nicotine craving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients should suck the lozenge until it dissolves; lozenges should not be chewed or swallowed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most smokers should use the 2 mg dose lozenge. Patients with significant symptoms of nicotine dependence (eg, those who smoke within 30 minutes of awakening) may require the 4 mg lozenge.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients should start by taking one lozenge every 1 to 2 hours during the first few weeks of smoking cessation, then gradually decrease the frequency over the next two months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhalers*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotine inhalers are available by prescription.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The inhaler consists of a mouthpiece and a replaceable nicotine cartridge. When the smoker inhales through the cartridge, nicotine vapor is deposited in the mouth and throat and absorbed through the mucosa.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The pharmacokinetics of nicotine delivery are similar to gum, but some patients prefer the inhaler because its use mimics the action of smoking and provides some behavioral replacement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smokers should use the inhaler for a 20-minute puffing session about once an hour. Each cartridge can be used for four 20-minute puffing sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with significant symptoms of nicotine dependence should start with between 6 and 16 cartridges per day, and gradually decrease over up to 12 weeks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nasal spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicotine nasal spray is available by prescription.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal spray produces a more rapid rise in nicotine level than orally-absorbed products (gum, lozenge, and inhaler), so it may provide the most rapid relief of nicotine craving symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Studies of nasal spray in adolescents had a high drop-out rate due to irritant side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The main side effects are nasal irritation and burning, as well as unpleasant taste and smell; all of these tend to improve after a few days of use but may not resolve completely.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients should use one spray in each nostril, without sniffing or inhaling, and should not blow their nose for 2 to 3 minutes after spraying.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The spray is used at least 8 times per day, with a maximum of 5 doses per hour or 40 doses per day. The frequency of use is gradually decreased over 2 to 3 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Combination therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combining nicotine replacement products increases abstinence rates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The nicotine patch is usually combined with one of the oral products (gum, lozenge or nasal spray). The patch provides a steady level of nicotine to prevent withdrawal symptoms, and the oral product can provide a more rapid surge of nicotine to respond to an acute craving to smoke.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If products are combined, the optimal dose may be less than those outlined above. For example, if a patch effectively reduces nicotine craving, a patient may choose to use nicotine gum or lozenge only a few times a day, when they have an acute urge to smoke.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All forms of nicotine replacement therapy (NRT) are not recommended for nonsmokers. NRT is safer and less addictive than cigarettes and does not create a new addiction. The safety and effectiveness of nicotine replacement products in patients below the age of 18 years have not been established. However, no specific medical risk is known or expected in nicotine dependent adolescents. For any product one must decide whether the potential benefits justify the potential risk. Because some nicotine replacement products are available over the counter and may be accessible to teens, adolescents who indicate that they plan to use them should be counseled regarding proper use.",
"    <div class=\"footnotes\">",
"     * Oral products can be used on a regular schedule to avoid nicotine withdrawal symptoms, and can also be used to relieve acute urges to smoke. Each of these may have an initial unpleasant taste, which can be a barrier to correct use; most users become tolerant to the taste within a few days. Patients should not eat or drink acidic beverages (coffee, juice, or soda) for 15 minutes before or during use of these oral products.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Joseph Rosen and Marianna Sockrider, and from Kozlowski et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav. 2007; 32:2140.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10238=[""].join("\n");
var outline_f9_63_10238=null;
var title_f9_63_10239="Fibula fracture above lateral malleolus";
var content_f9_63_10239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibula fracture above the lateral malleolus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAQYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5q0Jv9LI9RXXWBwxHvXH6If8ATcf7NdfZcP8AjQBtxdOPWrC5x1qtB0qyORQBIpNdx8MVy963P3lx+VcMO3vXf/DBf9Gu2x1lA/QUAdbqxPyrntmqCYb5fbirmsH96D6ACqCnLgqaAOk0f/j3NYXjB9kTjdjitzRx+5b0rnPHB+UjPWgDnIOFHpVtDxkA5qlAQRVxOAATzQBKCdvOc0yU4BOOgp2cjjkim8u4QdCcD86APRNBjMem2y9xGDV+6OEAxUdou2NQMfKAKddN8w/WgCpJw1RN14qST1qFmLcdBQA0nI560w9Kd1/CkHUZ55zxQARsVYMD35q3sAxjp1qmv3j6dcVZikOCp9CQaANCAfKuOveib7ppkJJaMnoVNSzYxQB5B8UnzrFqnYRMcfjXA3R4Ck9TXcfE9yfEUa/3YB+rGuEuT8+D2BNAGc5HP6Vj6o+yNj0wK15BxjHauc8QSbLd+eTxQBzLNuYkjrQtNpy9KAFpR0pKKAuLiiiigLlrRuL9foa7KzYGVvbArjNI/wCP5PxrsbXAkoA24ORn2qyOgFVIDhRmrSngUAPHWvRfhkhGmyt6ymvOT1r0z4bDGjRnH3nY/rQBuasf9IY9MYqjCwzmrGrn982MnJqrB94CgDqtIGLbPqa5Px0+HX1JArq9HGLBP6Vxnjl83ae/WgDFtcYweKupzVCJiFwPpVyN+OnI7UATgnHr7VLYJ5moWqdjKpI/Gq6sM4z0rR8OJ5mtwD+4Gb9KAPRLfpnFQ3DZkPNWIeEqrIct9aAK0rYHNR5GOadJzkHrTCccUAITzkd6QnJ5xmk6n8KXOT0+lADgCRnp+tOiY+bz1PFNgJD889akIKyqQPmJoA0Lbqi445AqWcYU57VHadcnqtS3Odp96APEviW3/FUS5PCwp/WuHmyzOc9sCuz+Jhx4pn/65p/KuMOMNmgChOTtJrkvEsmWRK6y7YDOK4fXZN1+R6CgDOp/amU+gAooooAWikooAtaOM36D2NdnCgVgRyDXG6Hzfp9DXZRHJx7igDUtTxzzVxc78VSt/btVxTzQA5jzXqvw8Tbolt7gk/ma8oY8V6/4FTboVpn/AJ5g0ASatzMfrVW3Y76l1hv3rY6A1BZg7wO/egDtNOXbZRj1FefeNm/09R/tV6JajbBEPavNfGbg6zsBzgE0AUIscGrUVVYgBgGrCnvnn0oAlY9e1b3gtN+pTv2SPA/E/wD1q55zxzius8Cx/urmU/xMF/SgDsY+IqqTHBJq30iIqjMQSCenSgCu/wB7GaYTx04p7DJO6mEjmgBOufQGlA4z3poAAzS5yv8AWgBqfeJJOCe/6Vcj+YLu+8PSq3yk5/CrNvjdk85yMUAXLU4YD161YuAdtV7Y/Mp7mrM/3SKAPBvia2PFNyD/AHE/lXIPyvoBXVfE8/8AFW3I/wBlM/lXLyHEWAPegDMvCAGNef3zb7yVvfFd5qzhbaRvQV56x3Mzdyc0AJT6ZT6ACiiigAooooAuaJxej2FdfEcqTjuK5LQx/phOO1dZCfkJ96ANS19auIapWvIxV5aAEkJC17V4QXy9Csx38tf5V4pN/qz9K9y8PLs0q1X/AKZr/KgDK1IZl9utSaeuZ0z3ovU3Sew71Np6Zuo1x1YUAdbCPlTrwK8s8WNnxFOOm0DnHWvVUHzHFeSa+wfxFfHsHC/oKAI4/wAcetToeQe1QxDgDtUsYwByetAAxwSO3Wu78Ex40lW7u5b9a4OQ4UgcnFek+F4vJ0q3TuEoA2JSRGDVJyS3PFWrhvlA9BVJ+vJ4oAgY5JPrTWwOnrT25OT0IpmMtyetADQehHbtTgfpknGKQrlgFGcUqj5hwOaAHJ/F3weKlTgMU7cVEDgHb+FSIDkjjP8AOgDStwP3eO/I+uKsTY2fhmqsJyODyO1Wpf8AVjHpQB8//E8E+NLkDoVT+Vc1Nj5c9K6b4mg/8Jrce8SH9K5qdRtx04oA53xK4j052B65rhR0rsvGTbLJEH8RrjR0oAUDNOpoGadQAUUUUAFFFFAF3Rf+PlvwrrLb7p/CuT0Y4nP4V1docqaANS14Yc1fWs+37GrkZycZoAdIM7R3JAr3bTh5dig/uxj+VeH26eZd26f3pVH6ivcI8pYyY7JQBh3MmZOD3q5prj7XGrk7s5FZpJMwAx14rQt12anCOmCKAOzQZavGtRffruoE952/Q17NBzzXik7F9SvWHUzv/wChGgC3H1BI+lTL1AqvFyvFSjHHSgB23zJ40A+8QK9T0pNttGB2WvM9MQy6pbqfXNepWQ2xj2FABOxJPr0qq5zk1PM2Hx3zVZyCDjPXmgCI4J44/wAaQjPXpTjgf0pn8We9AAOhGcUAbe9NBOff1p4GT2z3oAcBnr1J4qWP5thODk7eKiUnlSOO1TQAB8DBx0P9aALsXDk+9W5MeX26cVSjPzkn2/Grr8REDGRQB4L8VAV8ZuR3gQ/zrlbgErxXX/FpMeLo2H8Vuv8A6Ea5Kbgj0yKAOL8dPhrdB9TXK10fjl86hEvopNc4OlADlpaRaWgAooooAKKKKALmkn9+a6m0OEb6VyWmH/SK6u1Iww6UAa8J4/CrUXWqNuc8VeTgDmgDR0ZfM1qxXjHmg/lzXszkLpspI6gDrXj3hZd+v2vtk/pXrV25/s5B03MPxxQBlEbp0A65BrSgAfVkJ9QBVOPi43Z4AzV3Tox9ribdn5hQB19ucMQcV4grZvLn3lcj8zXtoIXLegNeH2/zTO3csT+poA0IsjHFSKPT1pkXXHFPBGeooA1vDSCXV89lWvR4BiPPeuB8GRhruZ/oK78HEOOnHX0oArSHLc9ck1E2McemafKcEg1Gx47UARsQTTcDqD70/nOOKZnnigBMc/KPqacehXnn9abk45zQrZAODmgCQc/L2qwmSQRnCjvVZE+YZA+lWEIx7/yoAsoM+2au5JQg8YqlECWVc98fpV3IKkCgDxT4vpt8S2b/AN63I/JjXFOM9e2DXffGePbqemSdijrn8RXn0x2rn8KAPPvGLFtUXP8Ad/rWJWv4sOdUHsorIoActLSLS0AFFFFABRRRQBNp5xcfhXU2pwp+lcnaEi4WuqtDlceq0Aa9twOtXYySKz7U5UGrydPrQB0PhBc6wrAHha9OvWK21v688V5t4KH+nlsd69Dvn5jBPAUYoAjjOckj+HFaOjgGdcDpgms1SAhx6itLQ8i4WgDp7ghbWdifuxk/pXh9kSADXtert5ekXr9ALdzn/gNeKWZ/dKDjoKANKI5OelSHA71HCODTmJ25HJoA6/wPEDbu+OrV2EpITPAH0rnvB0WzTYjzkjca3ronYB69aAKjHJIxz3pM52j+dKxAYn6ikIxg9TigBudrYFNOCaCPnzjt1pWUDJzQAijggjjHQUYwxyBjtSLnpkDP6075eSMgUAOTA29asxkd8fSq6HjHTJ/KphyjAjDNj6UATpwQ+fUj37VatjuD/wCzxVU4VANxG0VatQu58d8mgDyz41xkJpcncSOv6D/CvMr1sQqO5r1r41RhtHs3A+5cDn6qa8e1FsIgoA4LxQP+Jgp9V/rWTWv4oGbqNvUGsigBQeadTO4p9ABRRRQAUUUUALAcTIfeuqsj8ox1xXJxn51Oe9dTYH5VoA1bMkKK0IzlcelZtl2rRi70Add4HGZi3ctXc3xxKo46D+VcV4GHy59W4rr7pw13gnG3Bz+FAEmRsX6881qaBgzqw6VlJjuMA1raHxOB0zyKAN/xDz4f1DH/AD7uP/HTXitn/q1z1xXtev8A/IAv8f8APF/5V4lZH92nvQBqIeOD+FDcbifSmRngAU85d0XjlgKAPTvDcflabACMYQfyq/N7ntUWnJstQOwUCnvgDn1/OgCsCC+cdc/zpSeMZHAFITgse/P4UvTg9hQAxT1BPHalJJOB/kUHrz+FKBnNADVHJGPzpVH6U4A8k5PejGeBjIx1oAUHAGBjn0qT/lpyc4qJfmYbc59amXCgjk5BzQBK2ChIPBXiprJsThecbT+dVzwmD0/lUlqR52STnJoA5L4wRb/C8jY/1cqN+uP614PqLfdGcgV9EfEyLzvCWogDkR7vyOa+b75ssfSgDl/E4yYmHqRWJXQeIRutgfQg1z9ABT6ZT6ACiiigAooooAav3hXUadyi1y1dTpv+qXFAGnZnkZrRjODx6VnWmcjnvV9e9AHdeBcCFWPck10Fw2+4Y8ZDAVheDV8uCMN1HNbbAiZzxzzxQBeTHzEk9q2NH+W7QdD0rGjB8oADknv3Fa+lPi5gbj5jj9KAOl1kbtDvBjJMTfyrw21OAAT04r3W++bSbkZ/gNeGMpju5U/uuR+GaAL8ZwtXNMj83U7Vev7wGqCAEA5zzWx4XUya1CMfdBagD0yD5YKjYkyc8jHapl+WBeccjpVV2Vn65APrQA3dhvalB+X3PHWkIAY7TmlyAo+uKAEbn6H9KdnkYyDSDG4YzTl56ZoAUfdO6kAyvTp0x604deeDQQcHI+Y0AIgJCA+hzTug4555oUYAGewpzZx/tA/nQA85KqCDgkn37f4U2NwHHqMn86Q5wADxjrmkB3N16Yx78UAQ+LofP0K9j67oHH/jpr5anbI+lfV+q/vdNkHcqRXyhdqUmmTH3HZfyNAGJrAzayfSucHTNdPqC7oXHtXMDuPSgAp9Mpy9MUALRRRQAUUUUAMNdRpfMC49q5c9K6PSpP8AR1wOgoA2rbhqvD+lULYdKvjpmgD0DRB5enxSDptX9RWtuzMcHdlutZmkJu8PQN3KqBVq1YlIwfvDt70AbGTiM5xWrpufPicjlTmsiMl0H4fWtSxzujb3x9KAOsuP+QdcZ/55mvFdUXbq9yPVt1e1y/NZSjrujOfyrxvxCm3ViRj5lBoAiiNdD4KQtqzMf4UAz+Nc6nAx+tdZ4EjzNLJ6kDpQB303y2496oLkNkgYJH54q7ckrEv1FU8fNx644+tADuCOO49KXr15ppGBkZ4OCDRyTweO1ADh244GKcF+XjjNAUYz684zT0AyeKAAD6daXblgT0IwBTgDtJGO/FKw2445Hf3oAaBn/H8aBwzn0A60q9OM5x0oxyQTk5A5oAYpPUgADGeKUD94RnuMn9KazDBHJzk5oBJcNzjdj6UAST82rJ36V8weKYPsviPUoDwFnYj6HmvpvduUZxkgn9K+evilam28XznGPORXH4cf0oA4e6GUYVyrDa7D3rq5BkMOtcvcDE7j3oAjpy02nLQAtFFFABRRRQAyug0n/ULV/wAE+K9J8O2lzFqnhLS9eeVwySXjODGAMbRt7d67zTfiN4ckhBX4beHk9hJJ/jQBS0/wX4kuNCttZtdGvLnTZwxjngTzQQrFTkLkrypHIHSsyRHQsjqVYcFSMEGvqLwH8VvB2l/D/TGupLTSpcS/8SuzV5TF+9ftg4z97kj71cn44+MvhrWVeKHwjDqfBCz6iqKV9wFBP5MDQByOiDPhiHnB2gj64p9kD3Oeams5ku9GSWC0htEcAiGDeUT6bmY/mar2WASCRuOc0AbkI4w3U9hWjZclcjHPrWVbsVUdMjg1q2hGV654JoA66I7rbnuhFeR+LV8vUI+PUV61aEm2A9uteXeO4/Lvo+ONxzQBiIx5rvfAse22Q44PNeel9oyfSvUPCEfladG3+zmgDbvHzIAO1Q4JIPU9M0SNu5OM8ZFL1BxzQAA4HPT0pwX5VI/PNDk8HuRwPwoGDnjuOtADlGDx1zU4HGaiCfN1+tSp93AyPagBePmz1NKRkggZ70dd3TikbOBwfSgBPUg9KNp9DmnHqQCecU0Ebic8DmgCMqMHk7aYW3Mwz6/gafypwRngn9M1FcPtiyMZwSD/AJ+tAECOQ6jPAwOevevIfjZa7NQ0+6UcMGQn9a9TLBZSzNldwHH1ri/jLZ+b4dSZRzBIrZ9uhoA8Ob77CuZvxtu3B9a6j/lpXOaym28J9RQBTpRSUUAPopBS0AFFFFADDyK3dFP7kelYVbmi8wigDo7XpVoVVtO1Wx0NAHpugjHhy1/3Af0pHBEsTLtG4ZIz1NLoPPhaHHUxg00APCST8y5I4oA1oCGGScgdvf8Azmta2OJRxnoeeh4rF02TfCpJ6juOvatW22hhnO0YGcUAdVpz/ugp64rhPiPDgxyY/jrtLFwAmO+Rmue+IVv5umSuBynP5UAedEZTC88ivXdIj8nTkXodoWvJ9OjNxe20QGQzDpXratsgCnHA5oAmz8v1bFSqMDOTnFV0yVwex3dKtAjbjjPYUAMxvHXgfypVGM9welGcbRjjocU4YyP50ASISQSOOec1KnQUxRhDtyPepUGTgdaAEByMAe9KFxgZ/wDrU/qeBxSEcDJ5oAZ3xzn9Ka55JPTOKfg7uB+NNcE9PzoAjbB4OcnI496pag2yPaBnkAEVfIGMDgjt+FZOqNgoo67jyOvegDKmkZQB2cjcSP8APeovGNv/AGn4QvI9uXMJyPfGf6Ukh+ZdxYZ98/xA5q9Awe2MBG4MCCR+VAHzIeqnHXrWJ4gXEqNXT61amx1W7tnBHkysv68Vz+uruhU+negDEooHSigBwpaRaWgAooooAZW3oZ/dmsStrQjlaAOmtV6HvVr+EkVWtB8tWj0oA9N8P5HhOE/7AH606xIIbKg55z+NJ4fwPClv6bASKdariRQFP17YoAs2g8qaSM5KH51z3FbELEohxgHgD0rOTBAwOnTir8XDgAYUt098UAblkRg7D918/nUPiOH7TpdwuM5U0aZIH3qPUZ9jU9x81s6nqUPFAHnPgi387Vw7DIiH5V36vmVhnKk4rm/DNr9ijuXYfvHkb8q3YTllcdCRQBqwfNt9Sdpqy33iMdBUNkoKgj+H/Gp2Axj1zQAgAxjp6HNC/MFA9ODTQDz3A4qSMDKj34xQBJGuRznNWEyOmPqahiyFGQRVheRgZGRQA1VGCCcHNJ1AHBGM1Ko+XGOfam44yDg9OKAIjxjHc+lI2WHXJHFSMNp6c4ppHyE9SDxQBGPvdMZzzmue1N8zHbkNn8OvH8q6BgEQDPCiuYu3PnhScYyxJ+v/AOugCjcPsGQBuKkA++MmnWNwyHHBGM/r0qtcHG1ztPTjJx3zTIm2mNlGF3KR9DkmgDzH4r2QtvEzTqvyXSBwfUjg1wGopvtWFez/ABYsRc6Da38YyYH5/wB1v/r14/OuYmFAHKjgkelLT5xslI9TTKAFHWnUynA5oAWiiigBorV0NiOKya0dGbEpHvQB19p0HNWz936VSsjwKuMflPvQB6joADeGLYEj7gxj6UiEttUNll5A9KPD52aBZnqoUZ9xipFRYsDrk5+o9aALqEFAM8DrV6PJkyx43jFUIWwgbC9s5HFXVb5fn4ORzjvQBo6aApkXpg9avhfMcL3zis2EqHwTkgYP59a2rIBpDMR8qjj3NAHPaliDUZIVA4Gcde1WLTPlqfz+ox/jUWuJnWdw7gZqa1cDaMAgkH685oA37JcRYGODT3QjcevOMZplmpMQGDwOakkOCQM8AfjQA0ccjOMdKkVc544JFNGBnBAAGalTJHNADwOvTJNTRD93wMZqPpjJPtUq8Jkjj1zQApI24J9MU0DG30HNPHzJkgUjAlQARgjrQAxguAeSB/jTH+6c1I3UgenFJJjZgEkHjFAEF0SltITzlTj8q5S65YklTuyPm6dzXUakxW1fHAOPy4rmLtVBOVwD+goAx7xihc7i2flA9+3H1qFZXE0TEceZtYY7dqkuhvJAJDfL/wDqqi5VgB6NkHPXvQBbvLVdT0K9spDuDqVXPvkivA7uNoXeKUYZCVYehr320k2kkdCoHPrXk/xH08WutSTRDEdyN49m7igDzbUU2y5qtWjqSArurOBzQAU5abSjrQA6iiigBlW9LYLcc1UqW1bbOp/CgDtrFuBV5j8tZNg+VBrT3ZjoA9U0PI0CzC9Nq5Pt3qUIgkyMkj3yMD/IqvpB26TagjooHXvirVpiSI7jghT170AWesbnqRz7EY6/rVqJt0YDZP8AOqhyYzu5UZUjHTAqe1fa6nquc80AaEJG8bOpBUV0lmMxqM9Bn/69c7ZKT5ZbAdfbuK6W1X5VA6DAFAGF4gjxeRvjIyU/Om2y5cAgDkDA7Voa+nClumaowqVYZUfSgDescsmAeMYx3NPcE5IHX17U3T02xM3H3cjH1pW5ycng9MUAGMjPt3qZMkY4qJdvGeuME4qSMcH3HrQBMvf26VYGdv545qGPuT3qUDqOfxoAAcp+HX3peN4BBIFH8Ldu3WkI6AE46UAMJ+bPAOaUAb+nvj1owQBngAfnTlQ4HYD1oAztaH+jbR1YgVzF0Cy4IOSMZB7Gup1pSVTPHOc+lc1eKVOAc4H0oAw7xvM3DH3ckepzWYeWyepOPwrRvQWOSePy57VRlQnAIOOQM+maAJbeUtAQwAf29QM/zrm/iHZi70qSVR+8h/ej6Z5/Q1uRlkwcYGenp0H6U24iN3bTwzKP4lJ/2W4P86APArtQUcVigYJHpXR38LQ3EsLjDIxU/UHFc/MNs7igBlLSUUAPFFIDRQA2lU4dT70lB6UAdTpsmUXmtmM5A9ziub0mQGMVv2zbmjXPVh/OgD1uzYJpsClTnHA/Cp7RjIZOMIoJP+FVF+W3hBGDtB5qazdldmxncM/TmgDSAIiY5OCd3tSW7ZZSep3Ajp3A/rSKSyD5uvK+4qSI/wB3lPU9qANfTmw0mRzyK6Wx4kVeo7ZrldNl2SFZiNpPTHTt/Wuqthhh9cf0oAg1xFMKF/mO7GKp2sKyRjA69cVra0heyYAAuMMBj0rHsX8uQ7mB3HgL0U/WgDoba3/0bKtyTR9mPTg8VPbEC3j2gdetSIWbgYHrQBVNoSPanraN0IwfarqFs4YD3FW4iBnIHHFAGZ9mYYypIoSJsHAOc1s7kAyRQHGBgZ9DQBkJbkgAj3p4hbp14rV4zwMUjDjgdfSgDIeBwORj2p6oQhJBHsatuSCck5qE7mYsefxoAwtbfA64A6461z12YpACsi5Pr9a6HXEw2dmQc5Hc1y94v3NyhQycnPIOemKAMy5hUygB1YcYwfyzWe0LGUovDISBnvnGP8KtSoGYhm2OBj68VUubh2EoZQCZAEYdTxzQA8OoWNmI4B4655wf1qpOxWedFGCvO7HVT3/A5qzIiEBGJy53Lj+93H41Xn2lYZQxO7KhvQj1/SgDybx9Z/ZfEEkgXCXCiYemTwf1Brh9QTEoPrXrvxGsRNottdoPngco3+63/wBcV5TqC5jB9KAKFFIvSloABzRSjgmigBKD0ooIyDQBq6Q3AGa6bTRuubcerr/OuV0rp+Nddoi79RtFI6yLQB6nI2QIxhtgGM/hmpYWKA4IYr1YdKrzjF2wORhgAR64qaHcGULnkEYz3oA1LXD7EOCBkHPbIP8AWpV2sq9sjPPTkYP8qbAoYN/CMnBx39asxR7hgk9PSgCSFd2dgyMZP0//AFV1mkvvgj3EFkGCe5rmba3JJHzYHGfauj0eFovoxOfagC/eEmMr/EV7Vg26lcKevQHtWveueFXO71qhp9m7yfPu68buKAN7TmJtQBk45yauoVyvHzfSjT7fbHg7Rx0xVloiwHAJ+lAEOQqgU4MOx5J4p7R5GNuOKFiOB0IFAD/X6cUBgqgEc03bwBz+FHzbfunJ9aAJQT96pRnJOcDrTFwQB09xTxx6UAI6bm+bk88gU026qpCjAPrVlcHGSfWnMvA4NAHK6zCxb5McHJFcpqjuiuSCvGRx3zXo17aiXqMjrWFqOjEoRj5D3XjFAHnLqQ7FkGMcDpkmsq8VmgBKEbTgYyfeuvvtKkhDKMsBzzWFdWzngbyMDdgZKmgChJMJJPIwVZkGXA4z2IpLiJntpWJ4+UgjpuB5/Oi4iYsGBwduCT0qSI+ZAEXlW6jPQj1oAx9YtEutMuLdslZ1ypx6jP8AOvDr6JkMkbjDKxU/UV7/AHKbQQuSgwB7Z614/wCNrL7Lr1wFHySgSD8ev60AcT0JHvRT7hds5plABRRRQAUvrSUE4FAGlo65x9a7bw4mdZsh/tiuO0Fd34V3PhdN2uWgx3J/SgD0AsDcStyF6nvT7T53DKT1Ocd6k8sZl9WHSpLaJkQ8cYIH6UAa8QQyHaeT1z0FaNumFXHQD8qy7RXAXGN4GM1swxgYBByOvagCza43dMLxjPetW2dlIGcgnis63ALAjoOOT3q1CW5CnnOcUARXl6EZn3DABH41gp4gO/AkbPQbaj8WrMkJjgDNJISFVaw7Dw/csB9puWB9FXOPxNAHpvhrXXmi2SykkevOa6CPUFPB25zgV55o+kSWpRobpzxgqyiultoLtYwSocE9m5oA6VLpCOAPwNTRyRsBzXN+c0X3wyjPerMd1kfKcj2oA3QqNkA07yhnNZMdyc4ORU63RyRmgDSERyOBTvLHcgVn/azg/N+tD3qKuWODQBohkU02S6RFJH51z9xqiKxAbmsu/wBZ2LndxnpQB0dxqm0jAzTYdRilbZIMAnGa881DxIkX32CjP5U+y1yKUgxyg/jQB3Gq2SPkgc44xXIX9qM4dMn16V2Nnc/atOgmyCSuOKytWtw8bMOuOnqKAOCv7YbXwu4Z+mPxrLt18qQsmCfulT1NdNqVuMEZYeh/pWG0e27XK4JIB9MUASOouEyq4dhjrzXlnxXs1hurKRRj5Shr1iHzDMnIGTyAK87+MKYjsTj7zn+VAHjWoLtkBHeq1aGqrwD71njpQAUUUUAFB6UUN0oA3/Dafumb3rtvCP8AyHYj2VWb9K4/w6v+hg+prs/CgxqspHVYWxn8KAPRY8sOTw6kj1PHP8qlhbJAGMkYIznHpVWz3yW0WCPlMkfPPB//AF1e0kt9pUOu6MsBkDOPfP4UAbdtAEwCQGwO/QValIiGCDjsB6Uunrb3LGRSxBONj4qSSyKMcYK565IoAltcHdtBwe+elWoCVlHBOe1M06zKqRI8eccY71qWtupuEOMMoJ5NAGbrlqPLhYjknn1qKC3UYUDitXVfmKqoOV5pbaLKj07mgCvFDgDsc9qtRIyrkdc/rU4ixz35qQLgBQBwOaACJ5M4yCvvU6LE5yYgD64pUQYwOlWIkB60AQSW8TZxuX1xULWgYnErD6rmtMxg9uKVYhgE0AY7WUzEEXH5rQNIdz89w+e+BW2IgMYFSKg7cUAYP/CPW7H968rDvhsVHdeFdNlQbjOp9Vf/ABrpNuO1Ky8DjnFAHlHizwC5tXk0u6Mjjkwz4Gfo3rXl0qXFncOjCSC4Q4ZW4Ir6c1CLdbsD0xXjvxPsEiFpcFcSO7LnvgDNAG18JNee/srzS7ts3EBEsZ/vIeD+R/nXYXwXoe2ea8T8AXh03xlYSg/LIWif3DD/APVXt14gfOCoU+poA5y7j3sd2cEVlvYF5AQQcDAx2NdE6KjEynr0z1NVpHiTJUAH1oAxRZtEys6n5ec15X8ZZlZbBeN5djjPbFejeKtdFnaHYRuavAvFWpyanqTSSMX2cAk0Ac1quPJ/GswdKu6k2VA96pUAFFFFABSN0paQ9KAOr8PgCxT6f1rsPCPOpSg94sfqK4/QzizUV13hJiNQl6Z8vHP1FAHomjqVU4x9+VuO2MYqx4blNtuEbMcsXdGPUewpmjxhzITwCG25/wBoAfzFV7HEZfcqDsODk9OM/WgDtLCOAv5iMCwPKqwBxitXjyR1k53e5BrmdNulicgyFoyccIOv1rft5meJCNm3Hy88mgC3YhEJABGe59a0LV8SEj6VjrOy8B0Mp4IxwKu2bqqDPUk0AWrld4YnkEgVLbRnoB9BUIbfIqqM+9aEK4DepoARo+Pm6GmKMEnIPbFWGVSFHp69qaByAozQAgyD8vrirsOOM/SoEhOeQQDV5YcHr6UAC4I65p4FCQELjI/KpBH15yaAG9KUepoCnrS5255oAB1GaUjj6CkI4zzTlz1NAEUkfmKRXlPxcizHZoRxHvfPueK9fjGciuG+JmlC+0uTHEkfIOOlAHhCO1tdQzpw0TBxj2r2XR9YXUdPjmiYNleMHoe4ryG6iZHZHBDDirXhrVm0q8KuxEEvX0BoA9HuromQ5JJz3OBVC7u9qsd2AOetZ17q9srCRm3DHIBrjfEHiRmLJbkZ6CgDL+IWtl52iibLEYGOw9a82lPBJrWv2aSZ5JGLOxySax7s4BNAGReNukH1qGnzcymmUAFFFFABSN0paD0oA6bRWzaiut8LN/p8gPdOPzFcZob/AOj4rrfDrbNSTnqp/wAaAPUtFlAm+ZVCtwfpx/hUM0J8+QEn7pPy8Y+lN0p9tyM/3vlPX1rUuIAJ1IwzZ+UnqRnkfXtQAtizeWHKquAoGeTnvzWoL1oIC5ZSq8Ku3ke9U7O0ZJpGK7kcDkn0/wA/pVTUi8uoGHaNicbi2MmgDbsryV2Ck7gOcjv9a0La8VWRWbvzjuawIZPsdlJMSowMdejU3wrI2papCpJYRqzH65oA9BsMsm8gjuf8K04x6/lVaGMKgTFX40JGTnjt6UAIFyRuGM1OigYK9TUchweTzSpJ83PT+lAFqNOeKnII6ioYGU9OB71ZI3A4NADAcU7PAx1p5jI5xzxTSvPTHFADYmzwfTrUfSTnkUqjk/SiUYIOOD1oAWQ9hSpnvUYHP4U9cgcdqAJY2AOD61Q1+3E0LBhkMpBq4X43AcUy7HmxNnkAUAfP3jGxWC4Eqrgg7G/pXIy4ORjivV/iXp22zmnjHG3cR6Ed68mfHNAFSaR9v3zgcDms64HzY7kZq/OB3PGOap43MzN6c0AYF8MP7ViXvQ1t35/eN6Vgag22M+uKAMknLsaSgUUAFFFFABQRkGiigDY0B+qmur0yUQ3tu+cANgn0zxXF6LJsu9vrXUxnIGD70Aeq2RPY4PHTrmustNkyqzEFTyfUN3xXn+g3v2izgkwdx4bnuOtdpolxu2KDubGMNxnnigDqUg2WxZgCfpwRn+dcvfRDzzJGdoc8nPf1966m+uVj00lTgKOuelcRqV6ssTrHIo4JJPrQBS8Tal5McVtGf3h+dyPU9P0rqPhHal4Lq6cZyfLB9e5rzLTrWa/vnXdl2bLOegFe++CNNWw0qGOIEIADz1b3NAG/BARlyfpUxb5c854FLNKOQvX2qszFzxzQAkrkMO9OjLZ46cDP5Uvlknkjp0qzBAQ2cZ4oAlj+6MjGKnRsHPNCRdc96mEY2+1AD1mGcN1FKQHBYVGUB4GBSRBwQScUAOKYBNMC5GD7VayCOcc8Um3aCRjNAFQjbnHPHFM5yQc+1TyKO+OKhBAP14oATrHg/jTI2OGX2qVcBlBGOKYVCz5Hc0AcH4+Uvpl2Fwf3bfLXhjZ9K928XzRPvhbIzJs+teP+JLJLWfzIiDGxxx2NAHOTgDAxyTVa4wqcVPN8zfXsKp3rDOMc0AYWoZ3t71zOquCQua6TUztauU1Bt01AFaiiigAooooAKKKKAJLd/LnRh6111pIHVT61xpz2rodGn3QqD1FAHYaBqAspikhIjZgwPYH3rto/EFnBb74pVEo6c+teaxnKg+tWUxkYFAHWan4xv7lTFEyeWeCdpGayl1CeRQGIA6VnqAATU1ohluYYs4DEAn0FAHpnw60r7SRIy/uyN5Prn1r2azfYmFAAAAGD0rznwY4isV2hVCKqjb3XtXc2k37vryRQBe3biMjAPenpjdtwOlNhA2huzVZggBOSMUASwRZxnByO1Xo0IHSi3hKkYxgVcC4GKAIlUd6fsyD2zUgX0qVYzxkigCqq4JHGfWn7MnpVtY1BHGTT1AzjFAFFl6fWjoT6VdMSnJqC5tmC8HIPPFAFRowVJPBqsy7Xxnk84qSYOoOSfrUAlw27r70ASOwEgGKYzBQW67aqTzM0vynHPapkO4Mo7igDzXXA9xq7EN8gYnB/WvO/Gm+O6W3OdqLuH416vqtsFnlXk4Oc+tefePbLcqXaj51+Uj1HrQB53NhRz25rNuG+c89a07kcYrLuB8xxQBjaoeBntXJXv+uNdZqByzA9hXKXwxckdqAIaKKKACiiigBT1pKcelNoAKt6bN5M4UnhqqUZwQ3cUAdvayh0xn3q1FJyAawtDuRKuD97FbGfnoAvqegq1p7AX0e7pg/hxVBJM4ye1T27n7ZCR13igD2nwqwbT4WPdQPfp/8ArruLMGTaq9e1efeGLgRbImGBkfjivTNBQJC9yw4XoD60AX2+RxGOwq9bLgAjJGapwqHYsTnNacHUc80AXLcnPr61axnGO9VokwQc1bVcrnPSgBQjDpzjmpgvTiiPt71KKAE4FGOc0uOenFOVdxx0oAZilGcY7VIEYHg0eWfUUAULu1Dqdp+WsOeNo8qwPpXXBRjBXmqV1bDk9jQByojbPyg5PeprZXEo3DjHOfWtdolHAGKiKr5gBAAoA5TV4cl3A+6cVwniO3EtlIhB4zjNem6pb/O+CdpNcXrlofLcEdc/WgDwvUYtqn8qyLhABkV1OqwcyA/wk1ztyP3RHtQByt6f3j965rUVxcZ9q6O+BDMa52/GZCaAKtFHYUUAFFFFADj0ptOJ7U2gAooooAu6LP5F/Hk/KTg11jnBHvXDKSjhh1BzXaRSCWBX9gaALUZB68EVr6Fbm61KMYyE+Y49qxU+7kd+Aa7bwpYGCye4kXDy8D6UAdRpE4+1qp+Vjxk9K9otU8vTraNOOhJz1rxC1jInhx1Z1HP1r3K1ObKPB+58tAFm33BQSoyT2q/DnGcZ+vWqMXLhRngYA9avxkjgc+tAFyJj1yCPSrkDblA9qoxHBHrV2E4AGKALPTFTKMbTjOe1RxgsQAO1WI48HnqKAH7c8EUCNRTh05ooATHHFJtx0p1FACKoAxk0yZcpxUncGiZQVoAyrhMZIHFU3QlwfetOQckGqUi7W6YzzQBl6gm4SA+nFctrcPmWjsowcV2Nwmdx+tcxejICnp1IoA8U1228u4dSDz0rib5dpkFeueNNOEZEyA7c15brkO0uQOaAOKvk5bPeubvx859q6y9Xd27Vy+prtc0AZvc0Udz9aKACiiigB3QUlKBSGgBKKKKAEaul0abdbBSckfLXNHqK3PDavPeRwIMs7YAoA7Tw/p5upgSvyKfzr0VIBGiRouVUAGszQLBbdI1VeAPz963yuD04zzQAunxqdStlAyu9R+te0WsLRWKgcnOc15h4R01r/WYSq/u0IYn39K9bm+R1jUDCr09aAGWy4CgHDVcUEHPaoY0O/wCU8npVvB4AGO9AD1ClhnPFaEAA/Ks+LmQYzWnbjsRQBahHb2qyOlRQj5elSjigAooprEnpxQA6im0oNAC07qB7U2loArzrkg4qnKmT05rRYdPrVV16kjmgDMnT5CSOgrAlswXLDd/hXQ3LYBHrVAD5unFAHGeJNM+0WUqAZBHFeGa/b4ByORwa+mLyHOeBjuK8Q+IelfYtWmATEUp3rgdM/wD16APIL2LaWyK5PW02nPcGu91OAjcCOQTXGeI4sRbj7ZoA5xe9LTVPNOoAKKKKAH00nNONNIoASil4o4oAZn567v4ZWBnv2uGHC/Kv9TXDKu5gF5JPAr2n4f6eLTTkyMEjFAHbWsQjHA7YHtVuG3e5mEMILSMcYHb61DGSSsajcWIAAr0LwZpITYGGGY5P/wBc0AbPgfRHsrQNsC8cE9Se5rpxp6s+8kl6sJiOEKBgDgAUiyEngGgBsdiu77xP1qc2inGW6Uu4gDHapRIducZ9aACG1AcHg+lX4oOAWHNVoXAYc1cE3A4oAeQBwO1JTd4o3ilcBxOKbTGcE0b6YD6KZvo30ASjpRTFel30rgO79arXBAHr1qffVWYhvxNAGVcnvnBqkSc89+a0LlcjBFU2QYA5H0pgQ8HIbpXF/EnSDd6X5qKDJDzn2ruNm04NMubZbqBo3HBG3nuKAPlDVbf5+QMgYNcL4rtilrL/ALua9q8e6FJpt9MmzCqcrgdRXmviay8/R5XUZZAe3bFAHlI606kxTuKAEopeKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This fracture is above the joint line and involves disruption of the syndesmosis.&nbsp;Such injuries&nbsp;require orthopedic referral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_63_10239=[""].join("\n");
var outline_f9_63_10239=null;
